

# ABALOPARATIDE

**Products Affected**

- TYMLOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## ABATACEPT IV

### Products Affected

- ORENCIA INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	RA, PJIA, PSA: INITIAL: 6 MOS, RENEWAL: 12 MOS. ACUTE GRAFT VERSUS HOST DISEASE (AGVHD): 1 MO.
<b>Other Criteria</b>	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA, PJIA, PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

# ABATACEPT SQ

**Products Affected**

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PJIA, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## ABEMACICLIB

### Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# ABIRATERONE

**Products Affected**

- *abiraterone acetate*
- *abirtega*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## ABIRATERONE SUBMICRONIZED

### Products Affected

- ABIRATERONE ACETATE MICRONIZED
- YONSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ACALABRUTINIB

### Products Affected

- CALQUENCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ACORAMIDIS

### Products Affected

- ATTRUBY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CARDIOMYOPATHY OF WILD TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM): INITIAL: 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS I, II, OR III HEART FAILURE, AND 2) DIAGNOSIS CONFIRMED BY (A) BONE SCAN (SCINTIGRAPHY) STRONGLY POSITIVE FOR MYOCARDIAL UPTAKE OF TC-99M-PYP, OR (B) BIOPSY OF TISSUE OF AFFECTED ORGAN(S) (CARDIAC AND POSSIBLY NON-CARDIAC SITES) TO CONFIRM AMYLOID PRESENCE AND CHEMICAL TYPING TO CONFIRM PRESENCE OF TRANSTHYRETIN (TTR) PROTEIN.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ATTR-CM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ATTR SPECIALIST, OR MEDICAL GENETICIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	ATTR-CM: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER ATTR-CM TTR STABILIZERS (E.G., TAFAMIDIS).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ADAGRASIB

### Products Affected

- KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ADALIMUMAB

### Products Affected

- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA-PED>=40KG CROHNS START
- HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## ADALIMUMAB-AATY

### Products Affected

- YUFLYMA (1 PEN)
- YUFLYMA (2 SYRINGE)
- YUFLYMA-CD/UC/HS STARTER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RA, PJA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA, PSO, PJA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## ADALIMUMAB-ADBIM

### Products Affected

- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RA, PJA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA, PSO, PJA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# AFATINIB

**Products Affected**

- GILOTRIF

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## ALECTINIB

### Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ALPELISIB-PIQRAY

### Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## AMIKACIN LIPOSOMAL INH

### Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE: RENEWAL: 1) NO POSITIVE MAC SPUTUM CULTURE AFTER CONSECUTIVE NEGATIVE CULTURES, AND 2) IMPROVEMENT IN SYMPTOMS. ADDITIONALLY, FOR FIRST RENEWAL, APPROVAL REQUIRES AT LEAST ONE NEGATIVE SPUTUM CULTURE FOR MAC BY SIX MONTHS OF ARIKAYCE TREATMENT. FOR SECOND AND SUBSEQUENT RENEWALS, APPROVAL REQUIRES AT LEAST THREE NEGATIVE SPUTUM CULTURES FOR MAC BY 12 MONTHS OF ARIKAYCE TREATMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	MAC LUNG DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR INFECTIOUS DISEASE SPECIALIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 6 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## AMIVANTAMAB-HYALURONIDASE-LPUJ

### Products Affected

- RYBREVANT FASPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## AMIVANTAMAB-VMJW

### Products Affected

- RYBREVANT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ANAKINRA

### Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS.
<b>Required Medical Information</b>	INITIAL: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES. DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. CAPS, DIRA: LIFETIME.
<b>Other Criteria</b>	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA.

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	RENEWAL: RA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## APALUTAMIDE

### Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## APOMORPHINE - ONAPGO

### Products Affected

- ONAPGO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PD: RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## APOMORPHINE - SL

### Products Affected

- KYNMOBI
- KYNMOBI TITRATION KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OF AGE OR OLDER.
<b>Prescriber Restrictions</b>	PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	PD: RENEWAL: IMPROVEMENT WITH MOTOR FLUCTUATIONS DURING OFF EPISODES WITH THE USE OF THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## APREMILAST

### Products Affected

- OTEZLA
- OTEZLA XR
- OTEZLA/OTEZLA XR INITIATION PK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: MILD PLAQUE PSORIASIS (PSO): 1) PSORIASIS COVERING LESS THAN 3 PERCENT OF BODY SURFACE AREA (BSA), 2) STATIC PHYSICIAN GLOBAL ASSESSMENT (SPGA) SCORE OF 2, OR 3) PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORE OF 2 TO 9. MODERATE TO SEVERE PSO: PSORIASIS COVERING 3 PERCENT OR MORE OF BSA, OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. BEHCETS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: MILD PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL SYSTEMIC THERAPY (E.G., METHOTREXATE, ACITRETIN, CYCLOSPORINE) OR ONE CONVENTIONAL TOPICAL THERAPY (E.G., TOPICAL CORTICOSTEROIDS). MODERATE TO SEVERE PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. BEHCETS

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	DISEASE: 1) HAS ORAL ULCERS OR A HISTORY OF RECURRENT ORAL ULCERS BASED ON CLINICAL SYMPTOMS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OR MORE CONSERVATIVE TREATMENTS (E.G., COLCHICINE, TOPICAL CORTICOSTEROID, ORAL CORTICOSTEROID). INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# ARIMOCLOMOL

**Products Affected**

- MIPLYFFA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NIEMANN-PICK DISEASE TYPE C (NPC): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH NEUROLOGIST OR GENETICIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	NPC: RENEWAL: IMPROVEMENT OR SLOWING OF DISEASE PROGRESSION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## ASCIMINIB

### Products Affected

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED OR T315I MUTATION PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SCEMBLIX IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## ASFOTASE ALFA

### Products Affected

- STRENSIQ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HYPOPHOSPHATASIA (HPP): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, GENETICIST, OR METABOLIC SPECIALIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PERINATAL/INFANTILE-ONSET HPP: 1) 6 MONTHS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC CHEST DEFORMITY, (II) CRANIOSYNOSTOSIS, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OF VITAMIN B6 DEPENDENT SEIZURES, (V) NEPHROCALCINOSIS OR HISTORY OF ELEVATED SERUM CALCIUM, (VI) HISTORY OR PRESENCE OF NON-TRAUMATIC POSTNATAL FRACTURE AND DELAYED FRACTURE HEALING. JUVENILE-ONSET HPP: 1) 18 YEARS OF

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TNSALP ALPL GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALP LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PLP LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PEA LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC DEFORMITIES, (II) PREMATURE LOSS OF PRIMARY TEETH PRIOR TO 5 YEARS OF AGE, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OR PRESENCE OF NON-TRAUMATIC FRACTURES OR DELAYED FRACTURE HEALING. ALL INDICATIONS: 1) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE, 2) CALCIUM OR PHOSPHATE LEVELS ARE NOT BELOW THE NORMAL RANGE, 3) NOT HAVE A TREATABLE FORM OF RICKETS. RENEWAL: ALL INDICATIONS: 1) IMPROVEMENT IN THE SKELETAL CHARACTERISTICS OF HPP, AND 2) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# ATOGEPANT

**Products Affected**

- QULIPTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## AVACOPAN

### Products Affected

- TAVNEOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS: INITIAL: ANCA SEROPOSITIVE (ANTI-PR3 OR ANTI-MPO).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ANCA-ASSOCIATED VASCULITIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 6 MONTHS.
<b>Other Criteria</b>	ANCA-ASSOCIATED VASCULITIS: RENEWAL: CONTINUES TO BENEFIT FROM THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## AVAPRITINIB

### Products Affected

- AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## AVUTOMETINIB-DEFACTINIB

### Products Affected

- AVMAPKI FAKZYNJA CO-PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## AXATILIMAB-CSFR

### Products Affected

- NIKTIMVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CHRONIC GRAFT VS HOST DISEASE (CGVHD): 1) FAILURE OF AT LEAST TWO LINES OF SYSTEMIC THERAPY, ONE OF WHICH MUST BE A TRIAL OF OR CONTRAINDICATION TO JAKAFI, AND 2) NO CONCURRENT USE WITH JAKAFI, REZUROCK, OR IMBRUVICA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## AXITINIB

### Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# AZACITIDINE

**Products Affected**

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## AZTREONAM INHALED

### Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	7 YEARS OF AGE OR OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# BEDAQUILINE

**Products Affected**

- SIRTURO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 WEEKS
<b>Other Criteria</b>	N/A
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## BELIMUMAB

### Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. LUPUS NEPHRITIS (LN): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: SLE: CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. RENEWAL: SLE: PATIENT HAD CLINICAL IMPROVEMENT. LN: IMPROVEMENT IN RENAL RESPONSE FROM BASELINE LABORATORY VALUES (I.E., EGFR OR PROTEINURIA) AND/OR CLINICAL PARAMETERS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## BELUMOSUDIL

### Products Affected

- REZUROCK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CHRONIC GRAFT VS HOST DISEASE (CGVHD): 1) FAILURE OF AT LEAST TWO LINES OF SYSTEMIC THERAPY, ONE OF WHICH MUST BE A TRIAL OF OR CONTRAINDICATION TO JAKAFI, AND 2) NO CONCURRENT USE WITH JAKAFI, NIKTIMVO, OR IMBRUVICA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## BELZUTIFAN

### Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## BENDAMUSTINE

### Products Affected

- BENDAMUSTINE HCL  
INTRAVENOUS SOLUTION
- *bendamustine hcl intravenous solution  
reconstituted*
- BENDEKA
- VIVIMUSTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## BENRALIZUMAB

### Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE, OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ASTHMA: 1) CONTINUED USE OF ICS AND ONE

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## BETAINE

### Products Affected

- *betaine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## BEVACIZUMAB-BVZR

### Products Affected

- ZIRABEV

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## BEXAROTENE

### Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## **BINIMETINIB**

### **Products Affected**

- MEKTOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## BORTEZOMIB

### Products Affected

- BORTEZOMIB INJECTION SOLUTION RECONSTITUTED 1 MG, 2.5 MG
- *bortezomib injection solution reconstituted 3.5 mg*
- BORUZU

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## BOSENTAN

### Products Affected

- *bosentan oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL: 1) DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASE IN BILIRUBIN BY 2 OR MORE TIMES ULN, AND 2) NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE. RENEWAL: NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## BOSUTINIB

### Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND BOSULIF IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

## BRIGATINIB

### Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## C1 ESTERASE INHIBITOR-HAEGARDA

### Products Affected

- HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HEREDITARY ANGIOEDEMA (HAE): INITIAL: 1) TYPE III HAE, OR 2) TYPE I OR II HAE CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTS: C1-INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, IMMUNOLOGIST, ALLERGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	HAE: INITIAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. RENEWAL: 1) IMPROVEMENT COMPARED TO BASELINE IN HAE ATTACKS (I.E., REDUCTIONS IN ATTACK FREQUENCY OR ATTACK SEVERITY), AND 2) NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## CABOZANTINIB CAPSULE

### Products Affected

- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## CABOZANTINIB TABLET

### Products Affected

- CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## CANNABIDIOL

### Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: DRAVET SYNDROME (DS), LENNOX-GASTAUT SYNDROME (LGS), TUBEROUS SCLEROSIS COMPLEX (TSC): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## CAPIVASERTIB

### Products Affected

- TRUQAP ORAL TABLET
- TRUQAP TABLET THERAPY PACK 160 MG ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## CAPMATINIB

### Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## CARGLUMIC ACID

### Products Affected

- carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ACUTE OR CHRONIC HYPERAMMONEMIA (HA) DUE TO N ACETYLGLUTAMATE SYNTHASE (NAGS) DEFICIENCY: NAGS GENE MUTATION IS CONFIRMED BY BIOCHEMICAL OR GENETIC TESTING. ACUTE HA DUE TO PROPIONIC ACIDEMIA (PA): 1) CONFIRMED BY ELEVATED METHYLCITRIC ACID AND NORMAL METHYLMALONIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE PCCA OR PCCB GENE. ACUTE HA DUE TO METHYLMALONIC ACIDEMIA (MMA): 1) CONFIRMED BY ELEVATED METHYLMALONIC ACID, METHYLCITRIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE MMUT, MMA, MMAB OR MMADHC GENES.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ACUTE HA DUE TO NAGS/PA/MMA: 7 DAYS. CHRONIC HA DUE TO NAGS: INITIAL: 6 MOS, RENEWAL: 12 MOS.
<b>Other Criteria</b>	RENEWAL: CHRONIC HA DUE TO NAGS: PATIENT HAS SHOWN CLINICAL IMPROVEMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## CERITINIB

### Products Affected

- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## CERTOLIZUMAB PEGOL

### Products Affected

- CIMZIA (1 SYRINGE) PREFILLED SYRINGE KIT 200 MG/ML SUBCUTANEOUS
- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG
- CIMZIA-STARTER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA, SELARSDI/YESINTEK, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA. AS: TRIAL OF

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ. CD: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: SELARSDI/YESINTEK, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA, SELARSDI/YESINTEK, SKYRIZI, TREMFYA, OTEZLA. NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL FOR RA, PSA, PSO, AS, CD, PJIA: TRIAL OF OR CONTRAINDICATION TO THE STEP AGENTS IS NOT REQUIRED IF THE PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL FOR RA, PSA, AS, PSO, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM THE MEDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# CETUXIMAB

**Products Affected**

- ERBITUX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## CLADRIBINE

### Products Affected

- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	48 WEEKS.
<b>Other Criteria</b>	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF TWO CYCLES IN EACH).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## CLOBAZAM-SYMPAZAN

### Products Affected

- SYMPAZAN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: LENNOX-GASTAUT SYNDROME (LGS): THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	LGS: INITIAL: CONTRAINDICATION TO OR UNABLE TO SWALLOW CLOBAZAM TABLETS OR SUSPENSION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## COBIMETINIB

### Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## CORTICOTROPIN

### Products Affected

- CORTROPHIN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	INITIAL: NOT APPROVED FOR DIAGNOSTIC PURPOSES.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MULTIPLE SCLEROSIS (MS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, ALLERGIST/IMMUNOLOGIST, OPHTHALMOLOGIST, PULMONOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INFANTILE SPASMS AND MS: 28 DAYS. ALL OTHER FDA APPROVED INDICATIONS: INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS: TRIAL OF OR CONTRAINDICATION TO INTRAVENOUS (IV) CORTICOSTEROIDS. RENEWAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MS: DEMONSTRATED CLINICAL BENEFIT WHILE ON THERAPY AS INDICATED BY SYMPTOM RESOLUTION AND/OR NORMALIZATION OF LABORATORY TESTS. PART B BEFORE PART D STEP THERAPY, APPLIES ONLY TO BENEFICIARIES IN AN MA-PD PLAN.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## CRIZOTINIB CAPSULE

### Products Affected

- XALKORI ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## CRIZOTINIB PELLETS

### Products Affected

- XALKORI ORAL CAPSULE SPRINKLE  
150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	NON-SMALL CELL LUNG CANCER (NSCLC), ANAPLASTIC LARGE CELL LYMPHOMA (ALCL), INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT); UNABLE TO SWALLOW CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## DABRAFENIB CAPSULES

### Products Affected

- TAFINLAR ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## DABRAFENIB SUSPENSION

### Products Affected

- TAFINLAR ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNABLE TO SWALLOW TAFINLAR CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## DACOMITINIB

### Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## DALFAMPRIDINE

### Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	MULTIPLE SCLEROSIS (MS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MS: INITIAL: HAS SYMPTOMS OF A WALKING DISABILITY (E.G., MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS, UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA). RENEWAL: IMPROVEMENT IN WALKING ABILITY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## DAROLUTAMIDE

### Products Affected

- NUBEQA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## DASATINIB

### Products Affected

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND DASATINIB IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## DATOPOTAMAB DERUXTECAN-DLNK

### Products Affected

- DATROWAY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## DECITABINE/CEDAZURIDINE

**Products Affected**

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## DEFERASIROX

### Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L. CHRONIC IRON OVERLOAD IN NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT): 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS), AND 2) LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G OF LIVER DRY WEIGHT OR GREATER. RENEWAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L. NTDT: 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) OR 2) LIC OF 3 MG FE/G OF LIVER DRY WEIGHT OR GREATER.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS OR NTDT: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS OR NTDT: DEFERASIROX SPRINKLE PACKETS: TRIAL OF OR CONTRAINDICATION TO GENERIC DEFERASIROX ORAL TABLET OR TABLET FOR ORAL SUSPENSION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## DENOSUMAB-BMWO - OSENVELT

### Products Affected

- OSENVELT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## DENOSUMAB-XGEVA

### Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## DEUTETRABENAZINE

### Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR PATIENT TITRATION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HUNTINGTON DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. TARDIVE DYSKINESIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TARDIVE DYSKINESIA: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## DEXTROMETHORPHAN QUINIDINE

**Products Affected**

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## DICLOFENAC TOPICAL SOLUTION

### Products Affected

- *diclofenac sodium external solution 2 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	OSTEOARTHRITIS OF THE KNEE: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DICLOFENAC SODIUM 1.5% TOPICAL DROPS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## DICLOFENAC-FLECTOR

### Products Affected

- *diclofenac epolamine external*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## DIMETHYL FUMARATE

### Products Affected

- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## DIROXIMEL FUMARATE

### Products Affected

- VUMERITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## DORDA VIPRONE

**Products Affected**

- MODEYSO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## DOSTARLIMAB-GXLY

### Products Affected

- JEMPERLI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## DRONABINOL CAPSULE

### Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY: TRIAL OF OR CONTRAINDICATION TO ONE ANTIEMETIC THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## DROXIDOPA

### Products Affected

- droxidopa*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH): INITIAL: 1) BASELINE BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE POSITION. 2) A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NOH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS RENEWAL: 12 MONTHS
<b>Other Criteria</b>	NOH: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## DUPILUMAB

### Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: EOSINOPHILIC ASTHMA: BLOOD EOSINOPHIL LEVEL OF 150 TO 1500 CELLS/MCL WITHIN THE PAST 12 MONTHS. EOSINOPHILIC ESOPHAGITIS (EOE): DIAGNOSIS CONFIRMED BY ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH BIOPSY. ATOPIC DERMATITIS (AD): AD COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR AD AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: AD, PN, CSU: PRESCRIBED OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST OR PULMONOLOGIST. CRSWNP: PRESCRIBED OR IN CONSULTATION WITH OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOE: PRESCRIBED OR IN CONSULTATION WITH GASTROENTEROLOGIST, ALLERGIST, OR IMMUNOLOGIST. COPD: PRESCRIBED OR IN CONSULTATION WITH PULMONOLOGIST. RENEWAL: CSU: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
<b>Coverage Duration</b>	BP: 12 MO. AD/CRSWNP/EOE/PN/CSU: INITIAL/RENEWAL: 6 MO/12 MO. ASTHMA/COPD: INITIAL/RENEWAL: 12 MO.
<b>Other Criteria</b>	INITIAL: AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID, CALCINEURIN INHIBITOR, PDE4 INHIBITOR, OR JAK INHIBITOR). ASTHMA: 1) CONCURRENT

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>                     THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY-TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS, OR ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 3) INADEQUATELY CONTROLLED DISEASE. PRURIGO NODULARIS (PN): CHRONIC PRURITUS (ITCH MORE THAN 6 WEEKS), MULTIPLE PRURIGINOUS LESIONS, AND HISTORY OR SIGN OF A PROLONGED SCRATCHING BEHAVIOR. EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. CHRONIC SPONTANEOUS URTICARIA (CSU): 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. INITIAL/RENEWAL : ALL INDICATIONS EXCEPT BULLOUS PEMPHIGOID (BP): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: AD, CRSWNP, EOE: IMPROVEMENT WHILE ON THERAPY. ASTHMA: 1) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. PN: IMPROVEMENT OR REDUCTION OF PRURITUS OR PRURIGINOUS LESIONS. EOSINOPHILIC COPD: 1) USED IN                 </p>

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	COMBINATION WITH A LAMA/LABA/ICS, AND 2) CLINICAL RESPONSE AS EVIDENCED BY (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS, OR (C) INCREASE IN FEV1 OF AT LEAST 5 PERCENT FROM PRETREATMENT BASELINE. CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## DUVELISIB

### Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## EFLORNITHINE

### Products Affected

- IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ELACESTRANT

### Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ELAGOLIX

### Products Affected

- ORLISSA ORAL TABLET 150 MG, 200 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
<b>Age Restrictions</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 18 YEARS OF AGE OR OLDER.
<b>Prescriber Restrictions</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 2) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND A PROGESTIN-CONTAINING PREPARATION. RENEWAL: 1) IMPROVEMENT IN PAIN ASSOCIATED WITH ENDOMETRIOSIS WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## ELAPEGADEMASE-LVLR

### Products Affected

- REVCOVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ADENOSINE DEAMINASE SEVERE COMBINED IMMUNE DEFICIENCY (ADA-SCID): INITIAL: ADA-SCID AS MANIFESTED BY: 1) CONFIRMATORY GENETIC TEST, OR 2) SUGGESTIVE LABORATORY FINDINGS (E.G., ELEVATED DEOXYADENOSINE NUCLEOTIDE [DAXP] LEVELS, LYMPHOPENIA) AND HALLMARK SIGNS/SYMPTOMS (E.G., RECURRENT INFECTIONS, FAILURE TO THRIVE, PERSISTENT DIARRHEA).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ADA-SCID: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH IMMUNOLOGIST, HEMATOLOGIST/ONCOLOGIST, OR PHYSICIAN SPECIALIZING IN INHERITED METABOLIC DISORDERS.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	ADA-SCID: RENEWAL: 1) IMPROVEMENT OR MAINTENANCE OF IMMUNE FUNCTION FROM BASELINE, AND 2) HAS NOT RECEIVED SUCCESSFUL HCT OR GENE THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ELEXACFTOR-TEZACFTOR-IVACFTOR

### Products Affected

- TRIKAFTA ORAL TABLET THERAPY • TRIKAFTA ORAL THERAPY PACK PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: LIFETIME.
Other Criteria	CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ELRANATAMAB-BCMM

### Products Affected

- ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RENEWAL: 1) HAS RECEIVED AT LEAST 24 WEEKS OF TREATMENT WITH ELREXFIO, AND 2) HAS RESPONDED TO TREATMENT (PARTIAL RESPONSE OR BETTER), AND HAS MAINTAINED THIS RESPONSE FOR AT LEAST 2 MONTHS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ELTROMBOPAG - ALVAIZ

### Products Affected

- ALVAIZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT IS LESS THAN $30 \times 10^9/L$ , OR 2) PLATELET COUNT IS LESS THAN $50 \times 10^9/L$ AND HAD A PRIOR BLEEDING EVENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
<b>Other Criteria</b>	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNT FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ELTROMBOPAG - PROMACTA

### Products Affected

- *eltrombopag olamine oral packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT OF LESS THAN 30 X 10 <sup>9</sup> /L, OR 2) PLATELET COUNT OF LESS THAN 50 X 10 <sup>9</sup> /L AND A PRIOR BLEEDING EVENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
<b>Other Criteria</b>	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR HAD AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). ALL INDICATIONS: ELTROMBOPAG ORAL SUSPENSION PACKETS: TRIAL OF A FORMULARY VERSION OF ELTROMBOPAG TABLET OR PATIENT IS UNABLE TO TOLERATE TABLET FORMULATION. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNTS FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## ENASIDENIB

### Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ENCORAFENIB

### Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ENSARTINIB

### Products Affected

- ENSACOVE ORAL CAPSULE 100 MG,  
25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ENTRECTINIB CAPSULES

### Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ENTRECTINIB PELLETS

### Products Affected

- ROZLYTREK ORAL PACKET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), SOLID TUMORS: 1) TRIAL OF OR CONTRAINDICATION TO ROZLYTREK CAPSULES MADE INTO AN ORAL SUSPENSION, AND 2) DIFFICULTY OR UNABLE TO SWALLOW CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ENZALUTAMIDE

### Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC): HIGH RISK FOR METASTASIS (I.E. PSA DOUBLING TIME OF 9 MONTHS OR LESS). METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), NON-METASTATIC CRPC (NMCRPC), METASTATIC CSPC (MCSPC), NMCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## EPCORITAMAB-BYSP

### Products Affected

- EPKINLY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## EPOETIN ALFA-EPBX

### Products Affected

- RETACRIT INJECTION SOLUTION                      UNIT/ML, 4000 UNIT/ML, 40000  
10000 UNIT/ML, 10000 UNIT/ML(1ML),              UNIT/ML  
2000 UNIT/ML, 20000 UNIT/ML, 3000

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CHRONIC KIDNEY DISEASE (CKD), ANEMIA RELATED TO ZIDOVUDINE, OR CANCER CHEMOTHERAPY: HEMOGLOBIN LEVEL IS LESS THAN 10G/DL. ELECTIVE, NON-CARDIAC, NON-VASCULAR SURGERY: HEMOGLOBIN LEVEL IS 13G/DL OR LESS. RENEWAL: 1) CKD IN ADULTS NOT ON DIALYSIS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS REACHED 10G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 2) CKD IN PEDIATRIC PATIENTS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS APPROACHED OR EXCEEDS 12G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 3) ANEMIA RELATED TO ZIDOVUDINE: HEMOGLOBIN LEVEL BETWEEN 10G/DL AND 12G/DL. 4) CANCER CHEMOTHERAPY: (A) HEMOGLOBIN LEVEL IS LESS THAN 10 G/DL, OR (B) HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ANEMIA FROM CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE: INITIAL/RENEWAL: 12 MONTHS. SURGERY: 1 MONTH.
<b>Other Criteria</b>	RENEWAL: CKD: NOT RECEIVING DIALYSIS TREATMENT. THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## ERDAFITINIB

### Products Affected

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ERENUMAB-AOOE

### Products Affected

- AIMOVIG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ERLOTINIB

### Products Affected

- *erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## ESKETAMINE

### Products Affected

- SPRAVATO (56 MG DOSE)
- SPRAVATO (84 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: TREATMENT-RESISTANT DEPRESSION (TRD), MAJOR DEPRESSIVE DISORDER (MDD): PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST OR OTHER REMS-CERTIFIED PROVIDER.
<b>Coverage Duration</b>	INITIAL: TRD: 3 MONTHS. MDD: 4 WEEKS. RENEWAL: TRD, MDD: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: TRD, MDD: 1) NON-PSYCHOTIC, UNIPOLAR DEPRESSION, AND 2) NO ACTIVE SUBSTANCE ABUSE. RENEWAL: TRD, MDD: DEMONSTRATED CLINICAL BENEFIT (IMPROVEMENT IN DEPRESSION) COMPARED TO BASELINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ETANERCEPT

### Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION.                      INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## EVEROLIMUS-AFINITOR

### Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## EVEROLIMUS-AFINITOR DISPERZ

### Products Affected

- *everolimus oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## FECAL MICROBIOTA CAPSULE

### Products Affected

- VOWST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	30 DAYS
<b>Other Criteria</b>	CLOSTRIDIODES DIFFICILE INFECTION (CDI): 1) HAS NOT PREVIOUSLY RECEIVED VOWST: COMPLETION OF ANTIBIOTIC TREATMENT FOR RECURRENT CDI (AT LEAST 3 CDI EPISODES), OR 2) PREVIOUSLY RECEIVED VOWST: (A) TREATMENT FAILURE (DEFINED AS THE PRESENCE OF CDI DIARRHEA WITHIN 8 WEEKS OF FIRST DOSE OF VOWST AND A POSITIVE STOOL TEST FOR C. DIFFICILE), AND (B) HAS NOT RECEIVED MORE THAN ONE TREATMENT COURSE OF VOWST WHICH WAS AT LEAST 12 DAYS AND NOT MORE THAN 8 WEEKS PRIOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## FEDRATINIB

### Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	MYELOFIBROSIS: INITIAL: TRIAL OF OR CONTRAINDICATION TO JAKAFI (RUXOLITINIB). RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## FENFLURAMINE

### Products Affected

- FINTEPLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME (LGS): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## FENTANYL CITRATE

### Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CANCER RELATED PAIN: 1) CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION, AND 2) TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT OR PATIENT HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## FEZOLINETANT

### Products Affected

- VEOZAH

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MENOPAUSAL VASOMOTOR SYMPTOMS (VMS): INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO HORMONAL THERAPY (E.G., ESTRADIOL TRANSDERMAL PATCH, ORAL CONJUGATED ESTROGENS), 2) LABORATORY TESTING TO ESTABLISH BASELINE HEPATIC FUNCTION AND CONTINUED MONITORING OF THESE VALUES IN ACCORDANCE WITH THE FDA CURRENT LABEL RECOMMENDATION, AND 3) NO CONCURRENT USE WITH ANOTHER HORMONAL (E.G., PREMPRO) OR NON-HORMONAL (E.G., BRISDELLE) AGENT FOR VMS. RENEWAL: 1) CONTINUED NEED FOR VMS TREATMENT (PERSISTENT HOT FLASHES), 2) REDUCTION IN VMS FREQUENCY OR SEVERITY DUE TO VEOZAH TREATMENT, AND 3) NO NEW SYMPTOMS OF LIVER INJURY AND/OR WORSENING LAB VALUES (E.G., ALT, AST, TOTAL BILIRUBIN).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## FILGRASTIM-AAFI

### Products Affected

- NIVESTYM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## FINERENONE

### Products Affected

- KERENDIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: HEART FAILURE (HF): 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS II-IV, AND 2) LEFT VENTRICULAR EJECTION FRACTION OF AT LEAST 40 PERCENT NOT DUE TO AN UNDERLYING CAUSE (E.G., INFILTRATIVE CARDIOMYOPATHY, HYPERTROPHIC CARDIOMYOPATHY, VALVULAR DISEASE, PERICARDIAL DISEASE, HIGH-OUTPUT HEART FAILURE).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: HF: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL:12 MONTHS
<b>Other Criteria</b>	CHRONIC KIDNEY DISEASE (CKD) ASSOCIATED WITH TYPE 2 DIABETES (T2D): INITIAL: HISTORY OF AND WILL CONTINUE ON, HAS A CONTRAINDICATION, OR INTOLERANCE TO AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE-I) OR AN ANGIOTENSIN RECEPTOR BLOCKER (ARB). HF: INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER MINERALOCORTICOID (ALDOSTERONE) RECEPTOR ANTAGONIST.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

# FINGOLIMOD

**Products Affected**

- *fingolimod hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## FOSCARBIDOPA-FOSLEVODOPA

### Products Affected

- VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 12 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PD: INITIAL: ONE OF THE FOLLOWING: 1) UNABLE TO SWALLOW EXTENDED-RELEASE (ER) TABLETS OR ADMINISTER ER CAPSULES VIA A FEEDING TUBE, OR 2) FAILURE TO ADHERE OR TOLERATE VIA A FEEDING TUBE AN ORAL CARBIDOPA/LEVODOPA REGIMEN. RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## FRUQUINTINIB

### Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## FUTIBATINIB

### Products Affected

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA): COMPLETE A COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## GALCANEZUMAB-GNLM

### Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: MIGRAINE PREVENTION: 6 MOS. EPISODIC CLUSTER HEADACHE: 3 MOS. RENEWAL (ALL): 12 MOS.
Other Criteria	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. EPISODIC CLUSTER HEADACHE: RENEWAL: IMPROVEMENT IN EPISODIC CLUSTER HEADACHE FREQUENCY AS COMPARED TO BASELINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# GANAXOLONE

**Products Affected**

- ZTALMY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## GEFITINIB

### Products Affected

- *gefitinib*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# GEPHIRONE

## Products Affected

- EXXUA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	MAJOR DEPRESSIVE DISORDER: INITIAL: TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENTS: TRINTELLIX AND ONE GENERIC ANTIDEPRESSANT. INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER 5-HT1A RECEPTOR AGONIST (E.G., BUSPIRONE). RENEWAL: RESPONSE TO OR REMISSION OF DEPRESSIVE SYMPTOMS WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## GILTERITINIB

### Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## GLASDEGIB

### Products Affected

- DAURISMO ORAL TABLET 100 MG,  
25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## GLATIRAMER

### Products Affected

- *glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## GLECAPREVIR/PIBRENTASVIR

### Products Affected

- MAVYRET ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) INTOLERANCE OR CONTRAINDICATION TO ONE OF THE PREFERRED FORMULARY AGENTS: HARVONI OR EPCLUSA, WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE, 3) NO CONCURRENT USE WITH THE FOLLOWING AGENTS: RIFAMPIN, ATAZANAVIR, CARBAMAZEPINE, EFAVIRENZ, DARUNAVIR, LOPINAVIR, RITONAVIR, ATORVASTATIN, LOVASTATIN, SIMVASTATIN, ROSUVASTATIN AT DOSES GREATER THAN 10MG, CYCLOSPORINE AT DOSES GREATER THAN 100MG PER DAY, MEDICATIONS CONTAINING MORE THAN 20MCG OF ETHINYL ESTRADIOL, EPCLUSA, HARVONI, VOSEVI, OR ZEPATIER, AND 4) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD PUGH B OR C).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## GLP1-DULAGLUTIDE

### Products Affected

- TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## GLP1-SEMAGLUTIDE

### Products Affected

- OZEMPIC (0.25 OR 0.5 MG/DOSE)
- OZEMPIC (1 MG/DOSE)
- SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- RYBELSUS (FORMULATION R2)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## GLP1-TIRZEPATIDE

### Products Affected

- MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## GOSERELIN

### Products Affected

- ZOLADEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
<b>Coverage Duration</b>	STAGE B2-C PROSTATIC CARCINOMA: 4 MOS. ENDOMETRIOSIS: 6 MOS PER LIFETIME. ALL OTHERS: 12 MONTHS.
<b>Other Criteria</b>	ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 6 MONTHS OF TREATMENT PER LIFETIME.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## GUSELKUMAB

### Products Affected

- TREMFYA INTRAVENOUS
- TREMFYA ONE-PRESS SUBCUTANEOUS SOLUTION PEN-INJECTOR
- TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML
- TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- TREMFYA-CD/UC INDUCTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	SAME INDICATION. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## IBRUTINIB

### Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CHRONIC GRAFT VS HOST DISEASE (CGVHD): NO CONCURRENT USE WITH JAKAFI, NIKTIMVO, OR REZUROCK.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## ICATIBANT

### Products Affected

- *icatibant acetate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HEREDITARY ANGIOEDEMA (HAE): INITIAL: 1) TYPE III HAE, OR 2) TYPE I OR II HAE CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTS: C1-INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, HEMATOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	HAE: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER MEDICATIONS FOR THE TREATMENT OF ACUTE HAE ATTACKS. RENEWAL: REDUCTION IN SEVERITY OR DURATION OF ATTACKS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## IDELALISIB

### Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## IMATINIB

### Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
<b>Other Criteria</b>	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## IMATINIB SOLUTION

### Products Affected

- IMKELDI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
<b>Other Criteria</b>	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. ALL INDICATIONS: UNABLE TO SWALLOW GENERIC IMATINIB TABLETS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# IMETELSTAT

**Products Affected**

- RYTELO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# IMLUNESTRANT

**Products Affected**

- INLURIYO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

# INAVOLISIB

**Products Affected**

- ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## INFLIXIMAB

### Products Affected

- *infliximab*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA, SELARSDI/YESINTEK, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA, SELARSDI/YESINTEK, SKYRIZI, TREMFYA, OTEZLA. AS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ. MODERATE

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>TO SEVERE CD: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: SELARSDI/YESINTEK, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA. UC: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: SELARSDI/YESINTEK, XELJANZ, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA. INITIAL/RENEWAL: RA, PSA, AS, PSO, MODERATE TO SEVERE CD, UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## INSULIN SUPPLIES PAYMENT DETERMINATION

---

### Products Affected

- ABOUTTIME PEN NEEDLE 30G X 8 MM
- ABOUTTIME PEN NEEDLE 31G X 5 MM
- ABOUTTIME PEN NEEDLE 31G X 8 MM
- ABOUTTIME PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM
- ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 1 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 1 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 1 ML
- ALCOHOL PREP PAD
- ALCOHOL PREP PAD 70 %
- ALCOHOL PREP PADS PAD 70 %
- ALCOHOL SWABS PAD
- ALCOHOL SWABS PAD 70 %
- AQ INSULIN SYRINGE 31G X 5/16" 1 ML
- AQINJECT PEN NEEDLE 31G X 5 MM
- AQINJECT PEN NEEDLE 32G X 4 MM
- ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 0.5 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 1 ML
- ASSURE ID PRO PEN NEEDLES 30G X 5 MM
- AUM ALCOHOL PREP PADS PAD 70 %
- AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM
- AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 6 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 8 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 5 MM

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- AUM MINI INSULIN PEN NEEDLE 33G X 6 MM
- AUM PEN NEEDLE 32G X 4 MM
- AUM PEN NEEDLE 32G X 5 MM
- AUM PEN NEEDLE 32G X 6 MM
- AUM PEN NEEDLE 33G X 4 MM
- AUM PEN NEEDLE 33G X 5 MM
- AUM PEN NEEDLE 33G X 6 MM
- AUM READYGARD DUO PEN NEEDLE 32G X 4 MM
- AUM SAFETY PEN NEEDLE 31G X 4 MM
- BD AUTOSHIELD DUO 30G X 5 MM
- BD ECLIPSE SYRINGE 30G X 1/2" 1 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.3 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.5 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 1 ML
- BD INSULIN SYRINGE 27.5G X 5/8" 2 ML
- BD INSULIN SYRINGE 27G X 1/2" 1 ML
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (RX)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE HALF-UNIT 31G X 5/16" 0.3 ML
- BD INSULIN SYRINGE MICROFINE 27G X 5/8" 1 ML
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE U-100 1 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.5 ML
- BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM
- BD PEN NEEDLE MINI U/F 31G X 5 MM
- BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM
- BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM
- BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM
- BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM
- BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 1 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8" 1 ML
- BD SWAB SINGLE USE REGULAR PAD
- BD SWABS SINGLE USE BUTTERFLY PAD
- BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64" 0.3 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.5 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 1 ML
- CAREFINE PEN NEEDLES 29G X 12MM
- CAREFINE PEN NEEDLES 30G X 8 MM
- CAREFINE PEN NEEDLES 31G X 6 MM
- CAREFINE PEN NEEDLES 31G X 8 MM
- CAREFINE PEN NEEDLES 32G X 4 MM
- CAREFINE PEN NEEDLES 32G X 5 MM
- CAREFINE PEN NEEDLES 32G X 6 MM
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.3 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 1 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH ALCOHOL PREP PAD 70 %
- CARETOUCH INSULIN SYRINGE 28G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 29G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH PEN NEEDLES 29G X 12MM
- CARETOUCH PEN NEEDLES 31G X 5 MM
- CARETOUCH PEN NEEDLES 31G X 6 MM
- CARETOUCH PEN NEEDLES 31G X 8 MM
- CARETOUCH PEN NEEDLES 32G X 4 MM
- CARETOUCH PEN NEEDLES 32G X 5 MM
- CARETOUCH PEN NEEDLES 33G X 4 MM
- CLEVER CHOICE COMFORT EZ 29G X 12MM
- CLEVER CHOICE COMFORT EZ 33G X 4 MM
- CLICKFINE PEN NEEDLES 31G X 8 MM
- CLICKFINE PEN NEEDLES 32G X 4 MM
- COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT ASSIST INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 27G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 0.5 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 1 ML
- COMFORT EZ PEN NEEDLES 31G X 5 MM
- COMFORT EZ PEN NEEDLES 31G X 6 MM
- COMFORT EZ PEN NEEDLES 31G X 8 MM
- COMFORT EZ PEN NEEDLES 32G X 4 MM
- COMFORT EZ PEN NEEDLES 32G X 5 MM
- COMFORT EZ PEN NEEDLES 32G X 6 MM
- COMFORT EZ PEN NEEDLES 32G X 8 MM
- COMFORT EZ PEN NEEDLES 33G X 4 MM
- COMFORT EZ PEN NEEDLES 33G X 5 MM
- COMFORT EZ PEN NEEDLES 33G X 6 MM
- COMFORT EZ PEN NEEDLES 33G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 30G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 4 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM
- CURITY ALCOHOL PREPS PAD 70 %
- CURITY ALL PURPOSE SPONGES PAD 2"X2"
- CURITY GAUZE PAD 2"X2"
- CURITY GAUZE SPONGE PAD 2"X2"
- CURITY SPONGES PAD 2"X2"
- CVS GAUZE PAD 2"X2"
- CVS GAUZE STERILE PAD 2"X2"
- CVS ISOPROPYL ALCOHOL WIPES

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- DERMACEA GAUZE SPONGE PAD 2"X2"
- DERMACEA IV DRAIN SPONGES PAD 2"X2"
- DERMACEA NON-WOVEN SPONGES PAD 2"X2"
- DERMACEA TYPE VII GAUZE PAD 2"X2"
- DIATHRIVE PEN NEEDLE 31G X 5 MM
- DIATHRIVE PEN NEEDLE 31G X 6 MM
- DIATHRIVE PEN NEEDLE 31G X 8 MM
- DIATHRIVE PEN NEEDLE 32G X 4 MM
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 1 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 1 ML
- DROPLET MICRON 34G X 3.5 MM
- DROPLET PEN NEEDLES 29G X 10MM
- DROPLET PEN NEEDLES 29G X 12MM
- DROPLET PEN NEEDLES 30G X 8 MM
- DROPLET PEN NEEDLES 31G X 5 MM
- DROPLET PEN NEEDLES 31G X 6 MM
- DROPLET PEN NEEDLES 31G X 8 MM
- DROPLET PEN NEEDLES 32G X 4 MM
- DROPLET PEN NEEDLES 32G X 5 MM
- DROPLET PEN NEEDLES 32G X 6 MM
- DROPLET PEN NEEDLES 32G X 8 MM
- DROPSAFE ALCOHOL PREP PAD 70 %
- DROPSAFE AUTOPROTECT DUO 31G X 4 MM
- DROPSAFE AUTOPROTECT DUO 31G X 5 MM
- DROPSAFE AUTOPROTECT DUO 31G X 8 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM
- DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.5 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 1 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 0.3 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 1 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 0.5 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 1 ML
- DRUG MART UNIFINE PENTIPS 31G X 5 MM
- EASY COMFORT ALCOHOL PADS PAD
- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 31G X 1/2" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- EASY COMFORT PEN NEEDLES 29G X 4MM
- EASY COMFORT PEN NEEDLES 29G X 5MM
- EASY COMFORT PEN NEEDLES 31G X 5 MM
- EASY COMFORT PEN NEEDLES 31G X 6 MM
- EASY COMFORT PEN NEEDLES 31G X 8 MM
- EASY COMFORT PEN NEEDLES 32G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 5 MM
- EASY COMFORT PEN NEEDLES 33G X 6 MM
- EASY GLIDE PEN NEEDLES 33G X 4 MM
- EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 %
- EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 31G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2" 1 ML
- EASY TOUCH INSULIN BARRELS U-100 1 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 1/2" 1 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- EASY TOUCH INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 27G X 5/8" 1 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY TOUCH PEN NEEDLES 29G X 12MM
- EASY TOUCH PEN NEEDLES 30G X 5 MM
- EASY TOUCH PEN NEEDLES 30G X 6 MM
- EASY TOUCH PEN NEEDLES 30G X 8 MM
- EASY TOUCH PEN NEEDLES 31G X 5 MM
- EASY TOUCH PEN NEEDLES 31G X 6 MM
- EASY TOUCH PEN NEEDLES 31G X 8 MM
- EASY TOUCH PEN NEEDLES 32G X 4 MM
- EASY TOUCH PEN NEEDLES 32G X 5 MM
- EASY TOUCH PEN NEEDLES 32G X 6 MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM
- EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM
- EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16" 1 ML
- EMBECTA AUTOSHIELD DUO 30G X 5 MM
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64" 0.3 ML
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 1 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EMBECTA INSULIN SYRINGE U-100 27G X 5/8" 1 ML
- EMBECTA INSULIN SYRINGE U-100 28G X 1/2" 1 ML
- EMBECTA INSULIN SYRINGE U-500
- EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM
- EMBECTA PEN NEEDLE NANO 32G X 4 MM
- EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM
- EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM
- EMBRACE PEN NEEDLES 29G X 12MM
- EMBRACE PEN NEEDLES 30G X 5 MM
- EMBRACE PEN NEEDLES 30G X 8 MM
- EMBRACE PEN NEEDLES 31G X 5 MM
- EMBRACE PEN NEEDLES 31G X 6 MM
- EMBRACE PEN NEEDLES 31G X 8 MM
- EMBRACE PEN NEEDLES 31G X 8 MM
- EMBRACE PEN NEEDLES 32G X 4 MM
- EQL ALCOHOL SWABS PAD 70 %
- EQL GAUZE PAD 2"X2"
- EQL INSULIN SYRINGE 29G X 1/2" 0.5 ML
- EQL INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EXEL COMFORT POINT INSULIN SYR 29G X 1/2" 0.3 ML
- EXEL COMFORT POINT INSULIN SYR 30G X 5/16" 0.3 ML
- EXEL COMFORT POINT PEN NEEDLE 29G X 12MM
- GAUZE PADS PAD 2"X2"
- GAUZE TYPE VII MEDI-PAK PAD 2"X2"
- GLOBAL ALCOHOL PREP EASE
- GLOBAL EASE INJECT PEN NEEDLES 29G X 12MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 5 MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 8 MM
- GLOBAL EASE INJECT PEN NEEDLES 32G X 4 MM
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.3 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.5 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.5 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 1 ML
- GNP ALCOHOL SWABS PAD
- GNP CLICKFINE PEN NEEDLES 31G X 6 MM
- GNP CLICKFINE PEN NEEDLES 31G X 8 MM
- GNP INSULIN SYRINGE 28G X 1/2" 1 ML
- GNP INSULIN SYRINGE 29G X 1/2" 1 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 1 ML
- GNP INSULIN SYRINGES 30G X 5/16" 1 ML
- GNP INSULIN SYRINGES 30GX5/16" 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGES 31GX5/16" 31G X 5/16" 0.3 ML
- GNP PEN NEEDLES 31G X 5 MM
- GNP PEN NEEDLES 32G X 4 MM
- GNP PEN NEEDLES 32G X 6 MM
- GNP STERILE GAUZE PAD 2"X2"
- GNP ULTRA COM INSULIN SYRINGE 29G X 1/2" 0.5 ML
- GNP ULTRA COM INSULIN SYRINGE 30G X 5/16" 1 ML
- GOODSENSE ALCOHOL SWABS PAD 70 %
- GOODSENSE CLICKFINE PEN NEEDLE 31G X 5 MM
- GOODSENSE PEN NEEDLE PENFINE 31G X 8 MM
- H-E-B INCONTROL ALCOHOL PAD
- H-E-B INCONTROL PEN NEEDLES 29G X 12MM
- H-E-B INCONTROL PEN NEEDLES 31G X 5 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 6 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 8 MM
- H-E-B INCONTROL PEN NEEDLES 32G X 4 MM
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 1 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 1 ML
- HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM
- HM STERILE ALCOHOL PREP PAD
- HM STERILE PADS PAD 2"X2"
- HM ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML
- HM ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM
- INSULIN SYRINGE 29G X 1/2" 0.3 ML
- INSULIN SYRINGE 29G X 1/2" 1 ML
- INSULIN SYRINGE 30G X 5/16" 1 ML
- INSULIN SYRINGE 31G X 5/16" 0.3 ML
- INSULIN SYRINGE 31G X 5/16" 0.5 ML
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.3 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.5 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 5/16" 0.5 ML (OTC)
- INSULIN SYRINGE/NEEDLE 27G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 1 ML
- INSUPEN PEN NEEDLES 31G X 5 MM
- INSUPEN PEN NEEDLES 31G X 8 MM
- INSUPEN PEN NEEDLES 32G X 4 MM
- INSUPEN PEN NEEDLES 33G X 4 MM
- INSUPEN SENSITIVE 32G X 6 MM
- INSUPEN SENSITIVE 32G X 8 MM
- INSUPEN ULTRAFIN 29G X 12MM
- INSUPEN ULTRAFIN 30G X 8 MM
- INSUPEN ULTRAFIN 31G X 6 MM
- INSUPEN ULTRAFIN 31G X 8 MM
- INSUPEN32G EXTR3ME 32G X 6 MM
- J & J GAUZE PAD 2"X2"
- KENDALL HYDROPHILIC FOAM DRESS PAD 2"X2"
- KENDALL HYDROPHILIC FOAM PLUS PAD 2"X2"
- KINRAY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- KMART VALU INSULIN SYRINGE 29G U-100 1 ML
- KMART VALU INSULIN SYRINGE 30G U-100 0.3 ML
- KMART VALU INSULIN SYRINGE 30G U-100 1 ML
- KROGER INSULIN SYRINGE 30G X 5/16" 0.5 ML
- KROGER PEN NEEDLES 29G X 12MM
- KROGER PEN NEEDLES 31G X 6 MM
- LEADER INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LEADER INSULIN SYRINGE 28G X 1/2" 1 ML
- LEADER UNIFINE PENTIPS 31G X 5 MM
- LEADER UNIFINE PENTIPS 32G X 4 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 5 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 8 MM
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.3 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- LITETOUCH PEN NEEDLES 29G X 12.7MM
- LITETOUCH PEN NEEDLES 31G X 5 MM
- LITETOUCH PEN NEEDLES 31G X 6 MM
- LITETOUCH PEN NEEDLES 31G X 8 MM
- LITETOUCH PEN NEEDLES 32G X 4 MM
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 1 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 1 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM
- MAXICOMFORT II PEN NEEDLE 31G X 6 MM
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 0.5 ML
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 1 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.5 ML
- MEDICINE SHOPPE PEN NEEDLES 29G X 12MM
- MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM
- MEDPURA ALCOHOL PADS 70 % EXTERNAL
- MEIJER ALCOHOL SWABS PAD 70 %
- MEIJER PEN NEEDLES 29G X 12MM
- MEIJER PEN NEEDLES 31G X 6 MM
- MEIJER PEN NEEDLES 31G X 8 MM
- MICRODOT PEN NEEDLE 31G X 6 MM
- MICRODOT PEN NEEDLE 32G X 4 MM
- MICRODOT PEN NEEDLE 33G X 4 MM
- MIRASORB SPONGES 2"X2"
- MM PEN NEEDLES 31G X 6 MM
- MM PEN NEEDLES 32G X 4 MM
- MONOJECT INSULIN SYRINGE 25G X 5/8" 1 ML
- MONOJECT INSULIN SYRINGE 27G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (RX)

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 31G X 5/16" 1 ML
- MONOJECT INSULIN SYRINGE U-100 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.5 ML (RX)
- MS INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MS INSULIN SYRINGE 31G X 5/16" 0.3 ML
- MS INSULIN SYRINGE 31G X 5/16" 0.5 ML
- MS INSULIN SYRINGE 31G X 5/16" 1 ML
- NOVOFINE AUTOCOVER 30G X 8 MM
- NOVOFINE PEN NEEDLE 32G X 6 MM
- NOVOFINE PLUS PEN NEEDLE 32G X 4 MM
- NOVOTWIST PEN NEEDLE 32G X 5 MM
- PC UNIFINE PENTIPS 31G X 5 MM
- PC UNIFINE PENTIPS 31G X 6 MM
- PC UNIFINE PENTIPS 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 32G X 4 MM
- PEN NEEDLES 30G X 5 MM (OTC)
- PEN NEEDLES 30G X 8 MM
- PEN NEEDLES 32G X 5 MM
- PENTIPS 29G X 12MM (RX)
- PENTIPS 31G X 5 MM (RX)
- PENTIPS 31G X 8 MM (RX)
- PENTIPS 32G X 4 MM (RX)
- PENTIPS GENERIC PEN NEEDLES 29G X 12MM
- PENTIPS GENERIC PEN NEEDLES 31G X 6 MM
- PENTIPS GENERIC PEN NEEDLES 32G X 6 MM
- PHARMACIST CHOICE ALCOHOL PAD
- PIP PEN NEEDLES 31G X 5MM 31G X 5 MM
- PIP PEN NEEDLES 32G X 4MM 32G X 4 MM
- PRECISION SURE-DOSE SYRINGE 30G X 5/16" 0.3 ML
- PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 1 ML
- PREFERRED PLUS INSULIN SYRINGE 30G X 5/16" 1 ML
- PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM
- PREVENT SAFETY PEN NEEDLES 31G X 6 MM
- PREVENT SAFETY PEN NEEDLES 31G X 8 MM
- PRO COMFORT ALCOHOL PAD 70 %
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- PRO COMFORT PEN NEEDLES 32G X 4 MM
- PRO COMFORT PEN NEEDLES 32G X 5 MM
- PRO COMFORT PEN NEEDLES 32G X 6 MM
- PRO COMFORT PEN NEEDLES 32G X 8 MM
- PRODIGY INSULIN SYRINGE 28G X 1/2" 1 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.3 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PURE COMFORT ALCOHOL PREP PAD
- PURE COMFORT PEN NEEDLE 32G X 4 MM
- PURE COMFORT PEN NEEDLE 32G X 5 MM
- PURE COMFORT PEN NEEDLE 32G X 6 MM
- PURE COMFORT PEN NEEDLE 32G X 8 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM
- PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM
- PX SHORTLENGTH PEN NEEDLES 31G X 8 MM
- QC ALCOHOL
- QC ALCOHOL SWABS PAD 70 %
- QC BORDER ISLAND GAUZE PAD 2"X2"
- QUICK TOUCH INSULIN PEN NEEDLE 29G X 12.7MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM
- RA ALCOHOL SWABS PAD 70 %
- RA INSULIN SYRINGE 29G X 1/2" 0.5 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- RA INSULIN SYRINGE 29G X 1/2" 1 ML
- RA INSULIN SYRINGE 30G X 5/16" 0.5 ML
- RA INSULIN SYRINGE 30G X 5/16" 1 ML
- *ra isopropyl alcohol wipes*
- RA PEN NEEDLES 31G X 5 MM
- RA PEN NEEDLES 31G X 8 MM
- RA STERILE PAD 2"X2"
- RAYA SURE PEN NEEDLE 29G X 12MM
- RAYA SURE PEN NEEDLE 31G X 4 MM
- RAYA SURE PEN NEEDLE 31G X 5 MM
- RAYA SURE PEN NEEDLE 31G X 6 MM
- REALITY INSULIN SYRINGE 28G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 28G X 1/2" 1 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 1 ML
- REALITY SWABS PAD
- RELI-ON INSULIN SYRINGE 29G 0.3 ML
- RELI-ON INSULIN SYRINGE 29G X 1/2" 1 ML
- RELION ALCOHOL SWABS PAD
- RELION INSULIN SYRINGE 31G X 15/64" 0.3 ML
- RELION INSULIN SYRINGE 31G X 15/64" 0.5 ML
- RELION INSULIN SYRINGE 31G X 15/64" 1 ML
- RELION MINI PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 29G X 12MM
- RELION PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 8 MM
- RESTORE CONTACT LAYER PAD 2"X2"
- SAFETY INSULIN SYRINGES 29G X 1/2" 0.5 ML
- SAFETY INSULIN SYRINGES 29G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 5/16" 0.5 ML
- SAFETY PEN NEEDLES 30G X 5 MM
- SAFETY PEN NEEDLES 30G X 8 MM
- SB ALCOHOL PREP PAD 70 %
- SB INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SB INSULIN SYRINGE 29G X 1/2" 1 ML
- SB INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SB INSULIN SYRINGE 30G X 5/16" 1 ML
- SB INSULIN SYRINGE 31G X 5/16" 1 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 1 ML
- SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM
- SM ALCOHOL PREP PAD
- SM ALCOHOL PREP PAD 6-70 % EXTERNAL
- SM ALCOHOL PREP PAD 70 %
- SM GAUZE PAD 2"X2"
- STERILE GAUZE PAD 2"X2"
- STERILE PAD 2"X2"
- SURE COMFORT ALCOHOL PREP PAD 70 %
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE COMFORT PEN NEEDLES 29G X 12.7MM
- SURE COMFORT PEN NEEDLES 30G X 8 MM
- SURE COMFORT PEN NEEDLES 31G X 5 MM
- SURE COMFORT PEN NEEDLES 31G X 6 MM
- SURE COMFORT PEN NEEDLES 31G X 8 MM
- SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)
- SURE COMFORT PEN NEEDLES 32G X 4 MM (RX)
- SURE COMFORT PEN NEEDLES 32G X 6 MM
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE-PREP ALCOHOL PREP PAD 70 %
- SURGICAL GAUZE SPONGE PAD 2"X2"
- TECHLITE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- TECHLITE PEN NEEDLES 32G X 4 MM
- THERAGAUZE PAD 2"X2"
- TODAYS HEALTH PEN NEEDLES 29G X 12MM
- TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.5 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 1 ML
- TRUE COMFORT ALCOHOL PREP PADS PAD 70 %
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- TRUE COMFORT PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO ALCOHOL PREP PAD 70 %
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 1 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 1 ML
- TRUE COMFORT PRO PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 8 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM
- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 1 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 1 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.5 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUEPLUS PEN NEEDLES 29G X 12MM
- TRUEPLUS PEN NEEDLES 31G X 5 MM
- TRUEPLUS PEN NEEDLES 31G X 6 MM
- TRUEPLUS PEN NEEDLES 31G X 8 MM
- TRUEPLUS PEN NEEDLES 32G X 4 MM
- ULTICARE INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- ULTICARE INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 28G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 28G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (OTC)
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- ULTICARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 0.3 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 0.5 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 1 ML
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (OTC)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (RX)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (OTC)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (RX)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTICARE MICRO PEN NEEDLES 32G X 4 MM
- ULTICARE MINI PEN NEEDLES 30G X 5 MM
- ULTICARE MINI PEN NEEDLES 31G X 6 MM
- ULTICARE MINI PEN NEEDLES 32G X 6 MM
- ULTICARE PEN NEEDLES 29G X 12.7MM (OTC)
- ULTICARE PEN NEEDLES 29G X 12.7MM (RX)
- ULTICARE PEN NEEDLES 31G X 5 MM
- ULTICARE SHORT PEN NEEDLES 30G X 8 MM
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC)
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX)
- ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 1 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 1 ML
- ULTILET ALCOHOL SWABS PAD
- ULTILET PEN NEEDLE 29G X 12.7MM
- ULTILET PEN NEEDLE 31G X 5 MM
- ULTILET PEN NEEDLE 31G X 8 MM
- ULTILET PEN NEEDLE 32G X 4 MM
- ULTRA COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM
- ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM
- ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM
- ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRA THIN PEN NEEDLES 32G X 4 MM
- ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 1 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 1 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 0.5 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM
- ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM
- ULTRA-THIN II PEN NEEDLES 29G X 12.7MM
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRACARE PEN NEEDLES 31G X 5 MM
- ULTRACARE PEN NEEDLES 31G X 6 MM
- ULTRACARE PEN NEEDLES 31G X 8 MM
- ULTRACARE PEN NEEDLES 32G X 4 MM
- ULTRACARE PEN NEEDLES 32G X 5 MM
- ULTRACARE PEN NEEDLES 32G X 6 MM
- ULTRACARE PEN NEEDLES 33G X 4 MM
- UNIFINE OTC PEN NEEDLES 31G X 5 MM
- UNIFINE OTC PEN NEEDLES 32G X 4 MM
- UNIFINE PEN NEEDLES 32G X 4 MM
- UNIFINE PENTIPS 29G X 12MM
- UNIFINE PENTIPS 31G X 6 MM
- UNIFINE PENTIPS 31G X 8 MM
- UNIFINE PENTIPS 32G X 4 MM
- UNIFINE PENTIPS PLUS 29G X 12MM
- UNIFINE PENTIPS PLUS 31G X 6 MM
- UNIFINE PENTIPS PLUS 32G X 4 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 5 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 8 MM
- UNIFINE PROTECT PEN NEEDLE 32G X 4 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 5 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 6 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 8 MM
- UNIFINE ULTRA PEN NEEDLE 32G X 4 MM
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 1 ML
- VANISHPOINT INSULIN SYRINGE 29G X 5/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 1 ML

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN PEN NEEDLE 29G X 12MM
- VERIFINE INSULIN PEN NEEDLE 31G X 5 MM
- VERIFINE INSULIN PEN NEEDLE 32G X 6 MM
- VERIFINE INSULIN SYRINGE 28G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 30G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 1 ML
- VERIFINE PLUS PEN NEEDLE 31G X 5 MM
- VERIFINE PLUS PEN NEEDLE 31G X 8 MM
- VERIFINE PLUS PEN NEEDLE 32G X 4 MM
- VP INSULIN SYRINGE 29G X 1/2" 0.3 ML
- WEBCOL ALCOHOL PREP LARGE PAD 70 %
- WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM
- ZEVRX STERILE ALCOHOL PREP PAD PAD 70 %

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	LIFETIME
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## INTERFERON FOR MS-AVONEX

### Products Affected

- AVONEX PEN INTRAMUSCULAR  
AUTO-INJECTOR KIT
- AVONEX PREFILLED  
INTRAMUSCULAR PREFILLED  
SYRINGE KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## INTERFERON FOR MS-BETASERON

### Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## INTERFERON FOR MS-PLEGRIDY

### Products Affected

- PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## INTERFERON GAMMA-1B

### Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: CHRONIC GRANULOMATOUS DISEASE (CGD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, INFECTIOUS DISEASE SPECIALIST, OR IMMUNOLOGIST. SEVERE MALIGNANT OSTEOPETROSIS (SMO): PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR HEMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	RENEWAL: CGD, SMO: 1) DEMONSTRATED CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) HAS NOT RECEIVED HEMATOPOIETIC CELL TRANSPLANTATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## IPILIMUMAB

### Products Affected

- YERVOY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: UNRESECT/MET MEL: 4MO, RCC/CRC/HCC: 3MO, ALL OTHERS: 12MO. INITIAL/RENEWAL: CUTAN MEL: 6MO
<b>Other Criteria</b>	RENEWAL: ADJUVANT CUTANEOUS MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ISAVUCONAZONIUM

### Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INVASIVE ASPERGILLOSIS, INVASIVE MUCORMYCOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	INVASIVE ASPERGILLOSIS: TRIAL OF OR CONTRAINDICATION TO VORICONAZOLE. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## IVACFTOR

### Products Affected

- KALYDECO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT
<b>Coverage Duration</b>	INITIAL: 12 MONTHS. RENEWAL: LIFETIME
<b>Other Criteria</b>	CF: INITIAL: 1) NOT HOMOZYGOUS FOR F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## IVOSIDENIB

### Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## IXAZOMIB

### Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# LAMOTRIGINE

**Products Affected**

- SUBVENITE ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ALL INDICATIONS: CONTRAINDICATION TO OR UNABLE TO SWALLOW LAMOTRIGINE TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## LANREOTIDE

### Products Affected

- LANREOTIDE ACETATE
- SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 60 MG/0.2ML, 90 MG/0.3ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	ACROMEGALY: INITIAL: THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	ACROMEGALY: INITIAL/RENEWAL: 12 MOS. GEP-NETS, CARCINOID SYNDROME: 12 MOS.
Other Criteria	ACROMEGALY: RENEWAL: 1) REDUCTION, NORMALIZATION, OR MAINTENANCE OF IGF-1 LEVELS BASED ON AGE AND GENDER, AND 2) IMPROVEMENT OR SUSTAINED REMISSION OF CLINICAL SYMPTOMS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# LAPATINIB

## Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# LAROTRECTINIB

**Products Affected**

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	VITRAKVI ORAL SOLUTION: 1) TRIAL OF VITRAKVI CAPSULES, OR 2) UNABLE TO TAKE CAPSULE FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# LAZERTINIB

## Products Affected

- LAZCLUZE ORAL TABLET 240 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## LEDIPASVIR-SOFOSBUVIR

### Products Affected

- HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG
- HARVONI ORAL TABLET
- *ledipasvir-sofosbuvir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, AND 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, TIPRANA VIR/RITONAVIR, SOFOSBUVIR (AS A SINGLE AGENT), EPCLUSA, ZEPATIER, MAVYRET, OR VOSEVI.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# LENALIDOMIDE

**Products Affected**

- *lenalidomide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

# LENVATINIB

## Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## LETERMOVIR

### Products Affected

- PREVYMIS ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	HSCT: NOT AT RISK FOR LATE CMV: 4 MOS, AT RISK FOR LATE CMV: 7 MOS. KIDNEY TRANSPLANT: 7 MOS.
<b>Other Criteria</b>	HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 28 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 100 DAYS POST TRANSPLANT IF NOT AT RISK FOR LATE CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE, OR BEYOND 200 DAYS POST TRANSPLANT IF AT RISK FOR LATE CMV INFECTION AND DISEASE. KIDNEY TRANSPLANT: 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 7 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 200 DAYS POST TRANSPLANT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# LEUPROLIDE

## Products Affected

- *leuprolide acetate injection*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PROSTATE CANCER: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# LEUPROLIDE DEPOT

**Products Affected**

- LEUPROLIDE ACETATE (3 MONTH)
- LUTRATE DEPOT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## LEUPROLIDE MESYLATE

### Products Affected

- CAMCEVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## LEUPROLIDE-ELIGARD

### Products Affected

- ELIGARD

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## LEUPROLIDE-LUPRON DEPOT

### Products Affected

- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
<b>Coverage Duration</b>	PROSTATE CA: 12 MOS. UTERINE FIBROIDS: 3 MOS. ENDOMETRIOSIS: INITIAL/RENEWAL: 6 MOS.
<b>Other Criteria</b>	INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. RENEWAL: ENDOMETRIOSIS: 1) IMPROVEMENT OF PAIN RELATED TO ENDOMETRIOSIS WHILE ON THERAPY, 2) RECEIVING CONCOMITANT ADD-BACK THERAPY (I.E., COMBINATION ESTROGEN-PROGESTIN OR PROGESTIN-ONLY CONTRACEPTIVE PREPARATION), 3) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 4) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## LEUPROLIDE-LUPRON DEPOT-PED

### Products Affected

- LUPRON DEPOT-PED (3-MONTH)
- LUPRON DEPOT-PED (6-MONTH)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CENTRAL PRECOCIOUS PUBERTY (CPP): INITIAL: FEMALES: ELEVATED LEVEL OF LUTEINIZING HORMONE (LH) LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. MALES: ELEVATED LEVEL OF LH LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CPP: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	CPP: INITIAL: FEMALES: 1) YOUNGER THAN 8 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR BREAST DEVELOPMENT AND PUBIC HAIR GROWTH. MALES: 1) YOUNGER THAN 9 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR GENITAL DEVELOPMENT AND PUBIC HAIR GROWTH. RENEWAL: 1) TANNER STAGING AT INITIAL DIAGNOSIS HAS STABILIZED OR REGRESSED DURING THREE SEPARATE MEDICAL VISITS IN THE PREVIOUS YEAR, AND 2) HAS NOT REACHED ACTUAL AGE WHICH CORRESPONDS TO CURRENT PUBERTAL AGE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## L-GLUTAMINE

### Products Affected

- *l-glutamine oral packet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	SICKLE CELL DISEASE(SCD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST
<b>Coverage Duration</b>	INITIAL: 12 MONTHS. RENEWAL: LIFETIME.
<b>Other Criteria</b>	SCD: INITIAL: AGES 18 YEARS OR OLDER: 1) AT LEAST 2 SICKLE CELL CRISES IN THE PAST YEAR, 2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING, OR 3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME. AGES 5 TO 17 YEARS: APPROVED WITHOUT ADDITIONAL CRITERIA. RENEWAL: MAINTAINED OR EXPERIENCED A REDUCTION IN ACUTE COMPLICATIONS OF SCD.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## LIDOCAINE OINTMENT

### Products Affected

- *lidocaine external ointment 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## LIDOCAINE PRILOCAINE

### Products Affected

- *lidocaine-prilocaine external cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## LINVOSELTAMAB-GCPT

### Products Affected

- LYNOZYFIC INTRAVENOUS SOLUTION 200 MG/10ML, 5 MG/2.5ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## LONCASTUXIMAB TESIRINE-LPYL

### Products Affected

- ZYNLONTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## LORLATINIB

### Products Affected

- LORBRENA ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# LOTILANER

**Products Affected**

- XDEMVY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	DEMODEX BLEPHARITIS: 18 YEARS OF AGE OR OLDER
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 WEEKS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## LUMACFTOR-IVACFTOR

### Products Affected

- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CF EXPERT.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: LIFETIME.
<b>Other Criteria</b>	CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## MACITENTAN

### Products Affected

- OPSUMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## MARGETUXIMAB-CMKB

### Products Affected

- MARGENZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# MARIBAVIR

**Products Affected**

- LIVTENCITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## MAVACAMTEN

### Products Affected

- CAMZYOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY(HCM): INITIAL: LEFT VENTRICULAR OUTFLOW TRACK (LVOT) GRADIENT OF 50 MMHG OR HIGHER
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	OBSTRUCTIVE HCM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	OBSTRUCTIVE HCM: INITIAL: TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO A BETA-BLOCKER OR A NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER. RENEWAL: CONTINUED CLINICAL BENEFIT (E.G., REDUCTION OF SYMPTOMS, NYHA CLASSIFICATION IMPROVEMENT).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## MECASERMIN

### Products Affected

- INCRELEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	GROWTH FAILURE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	GROWTH FAILURE: INITIAL: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF WRIST AND HAND. INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER GROWTH HORMONE MEDICATION. RENEWAL: IMPROVEMENT WHILE ON THERAPY (INCREASE IN HEIGHT OR INCREASE IN HEIGHT VELOCITY).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## MECHLORETHAMINE

### Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## MEPOLIZUMAB

### Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY OR ALLERGY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOSINOPHILIC COPD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL: CRSWNP: 6 MO. OTHERS: 12 MO. RENEWAL: CRSWNP, ASTHMA, COPD, EGPA, HES: 12 MO.
<b>Other Criteria</b>	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 3) INADEQUATELY CONTROLLED DISEASE. EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. RENEWAL: ASTHMA: 1) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): 1) REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS, OR (C) INCREASE IN FEV1 OF AT LEAST 5 PERCENT FROM PRETREATMENT BASELINE.</p>
<b>Indications</b>	All FDA-approved Indications.

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# METYROSINE

## Products Affected

- *metirosine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PHEOCHROMOCYTOMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, ENDOCRINE SURGEON, OR HEMATOLOGIST-ONCOLOGIST.
<b>Coverage Duration</b>	PREOPERATIVE PREPARATION FOR SURGERY: 30 DAYS. MALIGNANT PHEOCHROMOCYTOMA: INITIAL/RENEWAL:12 MOS.
<b>Other Criteria</b>	PHEOCHROMOCYTOMA: INITIAL: HAS NON-METASTATIC PHEOCHROMOCYTOMA. PREOPERATIVE PREPARATION FOR SURGERY: USE IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR BLOCKER. RENEWAL: MALIGNANT PHEOCHROMOCYTOMA: STABLE OR CLINICAL IMPROVEMENT WHILE ON THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## MIDOSTAURIN

### Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## MIFEPRISTONE

### Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CUSHINGS SYNDROME (CS): INITIAL: DIAGNOSIS CONFIRMED BY: 1) 24-HR URINE FREE CORTISOL (AT LEAST 2 TESTS TO CONFIRM), 2) OVERNIGHT 1MG DEXAMETHASONE TEST, OR 3) LATE NIGHT SALIVARY CORTISOL (AT LEAST 2 TESTS TO CONFIRM).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	CS: INITIAL: HYPERCORTISOLISM IS NOT A RESULT OF CHRONIC GLUCOCORTICOIDS. RENEWAL: 1) CONTINUES TO HAVE IMPROVEMENT OF GLUCOSE TOLERANCE OR STABLE GLUCOSE TOLERANCE (E.G., REDUCED A1C, IMPROVED FASTING GLUCOSE), 2) CONTINUES TO HAVE TOLERABILITY TO THERAPY, AND 3) CONTINUES TO NOT BE A CANDIDATE FOR SURGICAL TREATMENT OR HAS FAILED SURGERY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## MILTEFOSINE

### Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## MIRDAMETINIB

### Products Affected

- GOMEKLI ORAL CAPSULE 1 MG, 2 MG
- GOMEKLI ORAL TABLET SOLUBLE MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## MIRVETUXIMAB SORAVTANSINE-GYNX

### Products Affected

- ELAHERE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: AN OPHTHALMIC EXAM, INCLUDING VISUAL ACUITY AND SLIT LAMP EXAM, WILL BE COMPLETED PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## MOMELOTINIB

### Products Affected

- OJJAARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## MOSUNETUZUMAB-AXGB

### Products Affected

- LUNSUMIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: INITIAL: 6 MONTHS. RENEWAL: 7 MONTHS.
<b>Other Criteria</b>	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: RENEWAL: 1) HAS ACHIEVED A PARTIAL RESPONSE TO TREATMENT, AND 2) HAS NOT PREVIOUSLY RECEIVED MORE THAN 17 CYCLES OF TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## NARCOLEPSY AGENTS

**Products Affected**

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## NAXITAMAB-GQGK

**Products Affected**

- DANYELZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## NERATINIB

### Products Affected

- NERLYNX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	EARLY-STAGE (STAGE I-III) BREAST CANCER: MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## NILOTINIB - TASIGNA

### Products Affected

- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND MEDICATION IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## NILOTINIB-DANZITEN

### Products Affected

- DANZITEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): 1) PERFORMED MUTATIONAL ANALYSIS PRIOR TO INITIATION OF THERAPY, AND 2) THERAPY IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## NINTEDANIB

### Products Affected

- OFEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 40% OF PREDICTED VALUE. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD): AT LEAST 10% FIBROSIS ON A CHEST HRCT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. SSC-ILD, PF-ILD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: SSC-ILD: 6 MOS. IPF, PF-ILD: 12 MOS. RENEWAL (ALL INDICATIONS): 12 MOS.
<b>Other Criteria</b>	INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ESBRIET (PIRFENIDONE). SSC-ILD: DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., HEART FAILURE/FLUID OVERLOAD, DRUG-INDUCED LUNG TOXICITY, RECURRENT ASPIRATION). PF-ILD: LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE WORSENERD/PROGRESSED DESPITE TREATMENT WITH

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	MEDICATIONS USED IN CLINICAL PRACTICE FOR ILD (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION, HEART FAILURE). RENEWAL: IPF, SSC-ILD, PF-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## NIRAPARIB

### Products Affected

- ZEJULA ORAL CAPSULE
- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: 1) ZEJULA WILL BE USED AS MONOTHERAPY, AND 2) ZEJULA IS STARTED NO LATER THAN 8 WEEKS AFTER THE MOST RECENT PLATINUM-CONTAINING REGIMEN.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## NIRAPARIB-ABIRATERONE

### Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# NIROGACESTAT

**Products Affected**

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

# NITISINONE

## Products Affected

- nitisinone*
- ORFADIN ORAL SUSPENSION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HEREDITARY TYROSINEMIA TYPE 1 (HT-1): INITIAL: DIAGNOSIS CONFIRMED BY ELEVATED URINARY OR PLASMA SUCCINYLACETONE LEVELS OR A MUTATION IN THE FUMARYLACETOACETATE HYDROLASE GENE. RENEWAL: URINARY OR PLASMA SUCCINYLACETONE LEVELS HAVE DECREASED FROM BASELINE WHILE ON TREATMENT WITH NITISINONE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HT-1: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PRESCRIBER SPECIALIZING IN INHERITED METABOLIC DISEASES.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	HT-1: INITIAL: ORFADIN SUSPENSION: TRIAL OF OR CONTRAINDICATION TO PREFERRED NITISINONE TABLETS OR CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# NIVOLUMAB

**Products Affected**

- OPDIVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## NIVOLUMAB-HYALURONIDASE-NVHY

### Products Affected

- OPDIVO QVANTIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## NIVOLUMAB-RELATLIMAB-RMBW

**Products Affected**

- OPDUALAG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## NOGAPENDEKIN ALFA

### Products Affected

- ANKTIVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	40 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## OFATUMUMAB SQ

### Products Affected

- KESIMPTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## OLAPARIB

### Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER: MEDICATION WILL BE USED AS MONOTHERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## OLUTASIDENIB

### Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# OMACETAXINE

**Products Affected**

- SYNRIBO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## OMALIZUMAB

### Products Affected

- XOLAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL OF AT LEAST 30 IU/ML. FOOD ALLERGY: 1) IGE SERUM LEVEL OF AT LEAST 30 IU/ML, AND 2) POSITIVE SKIN PRICK TEST TO AT LEAST ONE FOOD, OR POSITIVE MEDICALLY MONITORED FOOD CHALLENGE TO AT LEAST ONE FOOD.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL/RENEWAL: CHRONIC SPONTANEOUS URTICARIA (CSU): PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. INITIAL: CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. FOOD ALLERGY: PRESCRIBED BY OR IN CONSULTATION WITH ALLERGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: ASTHMA 12 MO/12 MO, CSU 6 MO/12 MO, CRSWNP 6 MO/12 MO, FOOD ALLERGY 12 MO/24 MO
<b>Other Criteria</b>	INITIAL: CSU: 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE, 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA ON MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS, AND 3) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: DUPIXENT. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>AGENTS: NUCALA, DUPIXENT, 3) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 4) INADEQUATELY CONTROLLED DISEASE. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA. FOOD ALLERGY: CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION .</p> <p>INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. CRSWNP: CLINICAL BENEFIT COMPARED TO BASELINE. ASTHMA: 1) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. FOOD ALLERGY: 1) PERSISTENT IGE-MEDIATED FOOD ALLERGY, AND 2) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## OSIMERTINIB

### Products Affected

- TAGRISSO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# OXANDROLONE

## Products Affected

- *oxandrolone oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	PROTEIN CATABOLISM, BONE PAIN: 1) MONITORED FOR PELIOSIS HEPATIS, LIVER CELL TUMORS, AND BLOOD LIPID CHANGES, 2) DOES NOT HAVE KNOWN OR SUSPECTED: CARCINOMA OF THE PROSTATE OR BREAST IN MALE PATIENTS, CARCINOMA OF THE BREAST IN FEMALES WITH HYPERCALCEMIA, NEPHROSIS (THE NEPHROTIC PHASE OF NEPHRITIS), OR HYPERCALCEMIA, AND 3) DOES NOT HAVE SEVERE HEPATIC DYSFUNCTION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## PACRITINIB

### Products Affected

- VONJO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## PALBOCICLIB

### Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## PASIREOTIDE DIASPARTATE

### Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CUSHINGS DISEASE (CD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	CD: RENEWAL: 1) CONTINUED IMPROVEMENT OF CUSHINGS DISEASE, AND 2) MAINTAINED TOLERABILITY TO SIGNIFOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## PAZOPANIB

### Products Affected

- *pazopanib hcl oral tablet 200 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED SOFT TISSUE SARCOMA (STS): NOT USED FOR ADIPOCYTIC STS OR GASTROINTESTINAL STROMAL TUMORS (GIST)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## PEGFILGRASTIM - APGF

### Products Affected

- NYVEPRIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## PEGFILGRASTIM - CBQV

### Products Affected

- UDENYCA ONBODY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	NON MYELOID MALIGNANCY: UDENYCA: TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT NYVEPRIA. UDENYCA ONBODY: 1) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT NYVEPRIA, OR 2) BARRIER TO ACCESS (E.G., TRAVEL BARRIERS, UNABLE TO RETURN TO CLINIC FOR INJECTIONS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## PEGINTERFERON ALFA-2A

### Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HEPATITIS B: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, OR PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G., HEPATOLOGIST).
<b>Coverage Duration</b>	HEP B/HEP C: 48 WEEKS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## PEGVISOMANT

### Products Affected

- SOMAVERT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

# PEMBROLIZUMAB

**Products Affected**

- KEYTRUDA INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# PEMBROLIZUMAB-BERAHYALURONIDASE ALFA-PMPH

**Products Affected**

- KEYTRUDA QLEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## PEMIGATINIB

### Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CHOLANGIOCARCINOMA, MYELOID/LYMPHOID NEOPLASMS: COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), WILL BE COMPLETED PRIOR TO INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## PENICILLAMINE TABLET

### Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CYSTINURIA: HAS NEPHROLITHIASIS AND ONE OF THE FOLLOWING: 1) STONE ANALYSIS SHOWING PRESENCE OF CYSTINE, 2) PRESENCE OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, OR 3) FAMILY HISTORY OF CYSTINURIA AND POSITIVE CYANIDE-NITROPRUSSIDE SCREENING.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: WILSONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. CYSTINURIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
<b>Other Criteria</b>	INITIAL: WILSONS DISEASE: 1) LEIPZIG SCORE OF 4 OR GREATER. RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) EXPERIENCED OR MAINTAINED IMPROVEMENT IN TENDER JOINT COUNT OR SWOLLEN JOINT COUNT COMPARED TO BASELINE. WILSONS DISEASE, CYSTINURIA: CONTINUES TO BENEFIT FROM THE MEDICATION.

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## PEXIDARTINIB

### Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## PIMAVANSERIN

### Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	PSYCHOSIS IN PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OR OLDER
<b>Prescriber Restrictions</b>	PSYCHOSIS IN PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (E.G., PSYCHIATRIST).
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PSYCHOSIS IN PD: RENEWAL: IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## PIRFENIDONE

### Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	IDIOPATHIC PULMONARY FIBROSIS (IPF): INITIAL: A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	IPF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	IPF: INITIAL: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, OR CANCER). RENEWAL: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## PIRTOBRUTINIB

### Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## POMALIDOMIDE

### Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## PONATINIB

### Products Affected

- ICLUSIG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CHRONIC MYELOID LEUKEMIA (CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND ICLUSIG IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## POSACONAZOLE TABLET

### Products Affected

- *posaconazole oral tablet delayed release*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE, PROPHYLAXIS: 6 MONTHS. TREATMENT: 12 WEEKS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## PRALSETINIB

### Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## PYRIMETHAMINE

### Products Affected

- *pyrimethamine oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	TOXOPLASMOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.
<b>Coverage Duration</b>	TOXOPLASMOSIS: INITIAL: 8 WEEKS, RENEWAL: 6 MOS.
<b>Other Criteria</b>	TOXOPLASMOSIS: RENEWAL: ONE OF THE FOLLOWING: (1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING), OR (2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENTLY TAKING AN ANTI-RETROVIRAL THERAPY IF HIV POSITIVE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# QUININE

**Products Affected**

- *quinine sulfate oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# QUIZARTINIB

**Products Affected**

- VANFLYTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## REGORAFENIB

### Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# RELUGOLIX

**Products Affected**

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## REPOTRECTINIB

### Products Affected

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## RESMETIROM

### Products Affected

- REZDIFFRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NONALCOHOLIC STEATOHEPATITIS (NASH): INITIAL: DIAGNOSIS CONFIRMED BY BIOPSY OR NONINVASIVE TESTING, OBTAINED IN THE PAST 12 MONTHS, DEMONSTRATING: 1) LIVER FIBROSIS STAGE 2 OR 3, OR 2) NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACTIVITY SCORE OF 4 OR MORE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NASH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST, GASTROENTEROLOGIST, OR ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	NASH: RENEWAL: CONTINUES TO HAVE NONCIRRHOTIC NASH WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## RETIFANLIMAB-DLWR

### Products Affected

- ZYNYZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## REVUMENIB

### Products Affected

- REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# RIBOCICLIB

**Products Affected**

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## RIBOCICLIB-LETROZOLE

### Products Affected

- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## RIFAXIMIN

### Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	TRAVELERS DIARRHEA, HEPATIC ENCEPHALOPATHY (HE): 12 MOS. IBS-D: 8 WKS.
Other Criteria	HE: TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

# RILONACEPT

**Products Affected**

- ARCALYST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES.</p> <p>DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS.</p> <p>RECURRENT PERICARDITIS (RP): TWO OF THE FOLLOWING: CHEST PAIN CONSISTENT WITH PERICARDITIS, PERICARDIAL FRICTION RUB, ECG SHOWING DIFFUSE ST-SEGMENT ELEVATION OR PR-SEGMENT DEPRESSION, NEW OR WORSENING PERICARDIAL EFFUSION.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CAPS, DIRA: LIFETIME. RP: 12 MONTHS.
<b>Other Criteria</b>	CAPS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	INHIBITOR, PDE-4 INHIBITOR) FOR CAPS. DIRA: 1) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR DIRA, AND 2) TRIAL OF THE PREFERRED AGENT: KINERET. RP: 1) HAD AN EPISODE OF ACUTE PERICARDITIS, 2) SYMPTOM-FREE FOR 4 TO 6 WEEKS, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR RP.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# RILUZOLE

## Products Affected

- TIGLUTIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 YEARS OR OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	AMYOTROPHIC LATERAL SCLEROSIS (ALS): (1) TRIAL OF RILUZOLE TABLETS, AND (2) PATIENT IS UNABLE TO TAKE TABLET FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## RIMEGEPANT

### Products Affected

- NURTEC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	ACUTE MIGRAINE TREATMENT: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN). INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR 2) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS. EPISODIC MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## RIOCIQUAT

### Products Affected

- ADEMPAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH): DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) (WHO GROUP 4): WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PAH, CTEPH: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PAH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE (PDE) INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. CTEPH: 1) NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS, AND 2) NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH OR HAS PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. RENEWAL: PAH, CTEPH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## RIPRETINIB

### Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## RISANKIZUMAB-RZAA

### Products Affected

- SKYRIZI
- SKYRIZI PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PLAQUE PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## RITUXIMAB AND HYALURONIDASE HUMAN-SQ

### Products Affected

- RITUXAN HYCELA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	FOLLICULAR LYMPHOMA (FL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 1) HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## RITUXIMAB-ABBS

### Products Affected

- TRUXIMA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA, PV: 12 MO. CLL: 6 MO.
<b>Other Criteria</b>	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: RA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## ROPEGINTERFERON ALFA-2B-NJFT

### Products Affected

- BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## RUCAPARIB

### Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# RUXOLITINIB

## Products Affected

- JAKAFI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	MYELOFIBROSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. POLYCYTHEMIA VERA, GVHD: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: CHRONIC GRAFT VS HOST DISEASE (CGVHD): NO CONCURRENT USE WITH REZUROCK, NIKTIMVO, OR IMBRUVICA. RENEWAL: MYELOFIBROSIS: CONTINUES TO BENEFIT FROM THE MEDICATION. CGVHD: NO CONCURRENT USE WITH REZUROCK, NIKTIMVO, OR IMBRUVICA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# SAPROPTERIN

**Products Affected**

- *javygtor oral tablet*
- *sapropterin dihydrochloride oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 2 MONTHS, RENEWAL 12 MONTHS.
<b>Other Criteria</b>	HYPERPHENYLALANINEMIA (HPA): INITIAL: NO CONCURRENT USE WITH PALYNZIQ. RENEWAL: 1) CONTINUES TO BENEFIT FROM TREATMENT, AND 2) NO CONCURRENT USE WITH PALYNZIQ.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## SECUKINUMAB SQ

### Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, ENTHESITIS-RELATED ARTHRITIS (ERA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: HS: 12 MONTHS, ALL OTHER INDICATIONS: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. AS, NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. ERA:

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	TRIAL OF OR CONTRAINDICATION TO ONE NSAID, SULFASALAZINE, OR METHOTREXATE. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## SELEXIPAG

### Products Affected

- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI TITRATION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	PAH: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: 1) FORMULARY VERSION OF AN ORAL ENDOTHELIN RECEPTOR ANTAGONIST, 2) FORMULARY VERSION OF AN ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, 3) FORMULARY VERSION OF AN ORAL CGMP STIMULATOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# SELINEXOR

## Products Affected

- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG, 40 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG, 80 MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## SELPERCATINIB

### Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## SELUMETINIB

### Products Affected

- KOSELUGO ORAL CAPSULE 10 MG, 25 MG
- KOSELUGO ORAL CAPSULE SPRINKLE 5 MG, 7.5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## SEVABERTINIB

### Products Affected

- HYRNUO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## SILDENAFIL TABLET

### Products Affected

- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: AGES 18 YEARS OR OLDER: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. AGES 1 TO 17 YEARS: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PAP GREATER THAN 20 MMHG, 2) PCWP OF 15 MMHG OR LESS, AND 3) PVR OF 3 WOOD UNITS OR GREATER.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## SIPONIMOD

### Products Affected

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## SIROLIMUS PROTEIN-BOUND

### Products Affected

- FYARRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## SODIUM OXYBATE-XYREM

### Products Affected

- sodium oxybate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: CATAPLEXY IN NARCOLEPSY, EXCESSIVE DAYTIME SLEEPINESS (EDS) IN NARCOLEPSY: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR SPECIALIST IN SLEEP MEDICINE
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: EDS IN NARCOLEPSY: 1) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT, AND 2) AGES 18 YEARS OR OLDER: TRIAL, FAILURE OF, OR CONTRAINDICATION TO A FORMULARY VERSION OF MODAFINIL, ARMODAFINIL, OR SUNOSI AND ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY. CATAPLEXY IN NARCOLEPSY: NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. RENEWAL: CATAPLEXY IN NARCOLEPSY, EDS IN NARCOLEPSY: 1) SUSTAINED IMPROVEMENT OF SYMPTOMS COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## SOFOSBUVIR/VELPATASVIR

### Products Affected

- EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG
- EPCLUSA ORAL TABLET
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANA VIR/RITONAVIR, TOPOTECAN, SOVALDI (AS A SINGLE AGENT), HARVONI, ZEPATIER, MAVYRET, OR VOSEVI, AND 3) PATIENTS WITH DECOMPENSATED CIRRHOSIS REQUIRE CONCURRENT RIBAVIRIN UNLESS RIBAVIRIN INELIGIBLE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

### Products Affected

- VOSEVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR, TIPRANAVIR/RITONAVIR, SOVALDI (AS A SINGLE AGENT), EPCLUSA, HARVONI, ZEPATIER, OR MAVYRET, AND 3) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## SOMATROPIN - NORDITROPIN

### Products Affected

- NORDITROPIN FLEXPRO  
SUBCUTANEOUS SOLUTION PEN-  
INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES.
<b>Required Medical Information</b>	INITIAL: PEDIATRIC GROWTH HORMONE DEFICIENCY (GHD), IDIOPATHIC SHORT STATURE (ISS), SMALL FOR GESTATIONAL AGE (SGA), NOONAN SYNDROME: HEIGHT AT LEAST 2 STANDARD DEVIATIONS BELOW THE MEAN HEIGHT FOR CHILDREN OF THE SAME AGE AND GENDER. TURNER SYNDROME (TS): CONFIRMED BY CHROMOSOMAL ANALYSIS (KARYOTYPING). PRADER WILLI SYNDROME (PWS): CONFIRMED GENETIC DIAGNOSIS OF PWS. ADULT GHD: 1) HAS A CONGENITAL, GENETIC, OR ORGANIC DISEASE (E.G., CRANIOPHARYNGIOMA, PITUITARY HYPOPLASIA, ECTOPIC POSTERIOR PITUITARY, PREVIOUS CRANIAL IRRADIATION), OR 2) GHD CONFIRMED BY ONE OF THE FOLLOWING GROWTH HORMONE (GH) STIMULATION TESTS: (A) INSULIN TOLERANCE TEST (PEAK GH OF 5 NG/ML OR LESS), (B) GLUCAGON-STIMULATION TEST (ONE OF THE FOLLOWING: (I) PEAK RESPONSE OF 3 NG/ML OR LESS AND BMI LESS THAN 25 KG/M2, (II) PEAK RESPONSE OF 3 NG/ML OR LESS AND BMI IS BETWEEN 25 - 30 KG/M2 WITH A PRE-TEST PROBABILITY, (III) PEAK RESPONSE OF 1 NG/ML OR LESS AND BMI IS BETWEEN 25 - 30 KG/M2 WITH LOW TEST PROBABILITY, OR (IV) PEAK RESPONSE OF 1 NG/ML OR LESS AND BMI IS GREATER THAN 30 KG/M2), OR (C) MACIMORELIN TEST (PEAK GH OF 2.8 NG/ML OR LESS).
<b>Age Restrictions</b>	SGA: 2 YEARS OF AGE OR OLDER.
<b>Prescriber Restrictions</b>	INITIAL/RENEWAL: ALL INDICATIONS: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	<p>INITIAL: PEDIATRIC GHD, ISS, SGA, TS, NOONAN SYNDROME: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. INITIAL/RENEWAL: ADULT GHD, PEDIATRIC GHD, SGA, TS, PWS, NOONAN SYNDROME: NO CONCURRENT USE WITH INCRELEX. RENEWAL: ISS: 1) IMPROVEMENT WHILE ON THERAPY (INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. PEDIATRIC GHD, SGA, TS, NOONAN SYNDROME: 1) IMPROVEMENT WHILE ON THERAPY (INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND OR HAS NOT COMPLETED PREPUBERTAL GROWTH. PWS: IMPROVEMENT IN BODY COMPOSITION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## SOMATROPIN - SEROSTIM

### Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
<b>Required Medical Information</b>	INITIAL: HIV/WASTING: ONE OF THE FOLLOWING FOR WEIGHT LOSS: 1) 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS OR 5% WEIGHT LOSS OVER 6 MONTHS, 2) 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, 3) BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, 4) BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND BMI LESS THAN 27 KG PER METER SQUARED, OR 5) BMI LESS THAN 20 KG PER METER SQUARED.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HIV/WASTING: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST, OR INFECTIOUS DISEASE SPECIALIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 9 MONTHS.
<b>Other Criteria</b>	HIV/WASTING: RENEWAL: 1) CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## SONIDEGIB

### Products Affected

- ODOMZO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC): BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## SORAFENIB

### Products Affected

- *sorafenib tosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## SOTATERCEPT-CSRK

### Products Affected

- WINREVAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL: 1) ON BACKGROUND PAH THERAPY (FOR AT LEAST 3 MONTHS) WITH AT LEAST TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: A) ORAL ENDOTHELIN RECEPTOR ANTAGONIST, B) ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, C) ORAL CGMP STIMULATOR, D) IV/SQ PROSTACYCLIN, OR 2) ON ONE AGENT FROM ONE OF THE ABOVE DRUG CLASSES, AND HAS A CONTRAINDICATION OR INTOLERANCE TO ALL OF THE OTHER DRUG CLASSES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## SOTORASIB

### Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# STIRIPENTOL

**Products Affected**

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	DRAVET SYNDROME: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## SUNITINIB

### Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO IMATINIB.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## TADALAFIL - ADCIRCA, ALYQ

### Products Affected

- *alyq*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM, AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## TADALAFIL-CIALIS

### Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	ERECTILE DYSFUNCTION WITHOUT DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH).
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	BPH: 1) TRIAL OF ONE ALPHA BLOCKER (E.G., DOXAZOSIN, TERAZOSIN, TAMSULOSIN, ALFUZOSIN), AND 2) TRIAL OF ONE 5-ALPHA-REDUCTASE INHIBITOR (E.G., FINASTERIDE, DUTASTERIDE). APPLIES TO 2.5MG AND 5MG STRENGTHS ONLY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## TAFAMIDIS

### Products Affected

- VYNDAMAX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CARDIOMYOPATHY ASSOCIATED WITH WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM): INITIAL: 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS I, II, OR III HEART FAILURE, AND 2) DIAGNOSIS CONFIRMED BY (A) BONE SCAN (SCINTIGRAPHY) STRONGLY POSITIVE FOR MYOCARDIAL UPTAKE OF TC-99M-PYP, OR (B) BIOPSY OF TISSUE OF AFFECTED ORGAN(S) (CARDIAC AND POSSIBLY NON-CARDIAC SITES) TO CONFIRM AMYLOID PRESENCE AND CHEMICAL TYPING TO CONFIRM PRESENCE OF TRANSTHYRETIN (TTR) PROTEIN.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ATTR-CM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ATTR SPECIALIST, OR MEDICAL GENETICIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	ATTR-CM: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER ATTR-CM TTR STABILIZERS (E.G., ACORAMIDIS)
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## TALAZOPARIB

### Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED OR METASTATIC BREAST CANCER: 1) HAS BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND 2) IF HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER, RECEIVED PRIOR TREATMENT WITH ENDOCRINE THERAPY OR IS CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

# TALETRECTINIB

**Products Affected**

- IBTROZI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# TALQUETAMAB-TGVS

**Products Affected**

- TALVEY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# TARLATAMAB-DLLE

**Products Affected**

- IMDELLTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

# TAZEMETOSTAT

**Products Affected**

- TAZVERIK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## TEBENTAFUSP-TEBN

### Products Affected

- KIMMTRAK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## TECLISTAMAB-CQYV

**Products Affected**

- TECVAYLI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## TELISOTUZUMAB VEDOTIN-TLLV

### Products Affected

- EMRELIS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# TELOTRISTAT

**Products Affected**

- XERMELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CARCINOID SYNDROME DIARRHEA: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST OR GASTROENTEROLOGIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# TEPOTINIB

**Products Affected**

- TEPMETKO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## TERIPARATIDE

### Products Affected

- TERIPARATIDE SUBCUTANEOUS SOLUTION PEN-INJECTOR 560 MCG/2.24ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY, UNLESS REMAINS AT OR HAS RETURNED TO HAVING A HIGH RISK FOR FRACTURE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## TESTOSTERONE

### Products Affected

- *testosterone gel 1.62 % transdermal*
- *testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## TESTOSTERONE CYPIONATE - DEPO

### Products Affected

- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## TESTOSTERONE ENANTHATE

### Products Affected

- *testosterone enanthate intramuscular solution*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: MALE DELAYED PUBERTY: 6MO, MALE HYPOGONADISM: 12 MO. OTHER INDICATIONS: 12 MO.
<b>Other Criteria</b>	INITIAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. MALE DELAYED PUBERTY: HAS NOT RECEIVED MORE THAN TWO 6-MONTH COURSES OF TESTOSTERONE REPLACEMENT THERAPY
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

# TETRABENAZINE

## Products Affected

- tetrabenazine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# THALIDOMIDE

## Products Affected

- THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## TISLELIZUMAB-JSGR

### Products Affected

- TEVIMBRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## TISOTUMAB VEDOTIN-TFTV

### Products Affected

- TIVDAK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# TIVOZANIB

**Products Affected**

- FOTIVDA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

## TOCILIZUMAB-AAZG IV

### Products Affected

- TYENNE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA, PJIA, SJIA, GCA: 6 MONTHS. CRS: 1 MONTH. RENEWAL: RA, PJIA, SJIA, GCA: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. GIANT CELL ARTERITIS (GCA): 1) HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICIDS, AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: RINVOQ. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ. RENEWAL: RA, PJIA, SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION.

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	GCA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## TOCILIZUMAB-AAZG SQ

### Products Affected

- TYENNE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. GIANT CELL ARTERITIS (GCA): 1) HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOID, AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: RINVOQ. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PJIA, SJIA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## TOFACITINIB

### Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, PCJIA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# TOLVAPTAN

**Products Affected**

- JYNARQUE ORAL TABLET
- *tolvaptan oral tablet therapy pack*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): INITIAL: CONFIRMED POLYCYSTIC KIDNEY DISEASE VIA CT, MRI, OR ULTRASOUND.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ADPKD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	ADPKD: INITIAL: DOES NOT HAVE ESRD (I.E., RECEIVING DIALYSIS). RENEWAL: HAS NOT PROGRESSED TO ESRD/DIALYSIS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## TOPICAL TRETINOIN

### Products Affected

- ALTRENO
- *tretinoin external gel 0.01 %, 0.025 %*
- *tretinoin external cream*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	COSMETIC INDICATIONS SUCH AS WRINKLES, PHOTOAGING, MELASMA.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	ACNE VULGARIS: BRAND TOPICAL TRETINOIN REQUIRES TRIAL OF OR CONTRAINDICATION TO A GENERIC TOPICAL TRETINOIN PRODUCT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

## TORIPALIMAB-TPZI

### Products Affected

- LOQTORZI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	NASOPHARYNGEAL CARCINOMA (NPC): FIRST LINE TREATMENT: 24 MOS, PREVIOUSLY TREATED: LIFETIME.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# TOVORAFENIB

**Products Affected**

- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# TRAMADOL

## Products Affected

- *tramadol hcl oral solution*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	PAIN: 1) TRIAL OF OR CONTRAINDICATION TO GENERIC TRAMADOL IMMEDIATE RELEASE TABLET OR GENERIC TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT, AND 2) UNABLE TO TAKE ORAL SOLID FORMULATIONS OF TRAMADOL OR TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT (E.G., DIFFICULTY SWALLOWING).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## TRAMETINIB SOLUTION

### Products Affected

- MEKINIST ORAL SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	UNRESECTABLE OR METASTATIC MELANOMA, MELANOMA, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC), UNRESECTABLE OR METASTATIC SOLID TUMOR, LOW-GRADE GLIOMA (LGG): UNABLE TO SWALLOW MEKINIST TABLETS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## TRAMETINIB TABLET

### Products Affected

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## TRASTUZUMAB-DKST

### Products Affected

- OGIVRI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## TRASTUZUMAB-HYALURONIDASE-OYSK

### Products Affected

- HERCEPTIN HYLECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADJUVANT BREAST CANCER, METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: HERZUMA, OGIVRI, ONTRUZANT, TRAZIMERA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# TRAZODONE

**Products Affected**

- RALDESY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	MAJOR DEPRESSIVE DISORDER (MDD); CONTRAINDICATION TO OR UNABLE TO SWALLOW TRAZODONE TABLETS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## TREMELIMUMAB-ACTL

### Products Affected

- IMJUDO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	UHCC: 30 DAYS. METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): 5 MONTHS.
<b>Other Criteria</b>	UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): HAS NOT RECEIVED PRIOR TREATMENT WITH IMJUDO. NSCLC: HAS NOT RECEIVED A TOTAL OF 5 DOSES OF IMJUDO.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## TRIENTINE CAPSULE

### Products Affected

- *trientine hcl oral capsule 250 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	WILSONS DISEASE: INITIAL: LEIPZIG SCORE OF 4 OR GREATER.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	WILSONS DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
<b>Other Criteria</b>	WILSONS DISEASE: INITIAL: TRIAL OF OR CONTRAINDICATION TO FORMULARY VERSION OF PENICILLAMINE TABLET. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## TRIFLURIDINE/TIPIRACIL

### Products Affected

- LONSURF ORAL TABLET 15-6.14 MG,  
20-8.19 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## TRIPTORELIN-TRELSTAR

### Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# TUCATINIB

## Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

# UBROGEPANT

## Products Affected

- UBRELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	ACUTE MIGRAINE TREATMENT: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## UPADACITINIB

### Products Affected

- RINVOQ
- RINVOQ LQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. AD: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST, OR IMMUNOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, AND 2) TRIAL OF OR CONTRAINDICATION TO A TOPICAL CORTICOSTEROID, TOPICAL CALCINEURIN INHIBITOR, TOPICAL PDE4 INHIBITOR, OR TOPICAL JAK INHIBITOR. AS,

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG). GIANT CELL ARTERITIS (GCA): HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOIDS.</p> <p>INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM THE MEDICATION. AD: IMPROVEMENT WHILE ON THERAPY.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## USTEKINUMAB-AAUZ SQ

### Products Affected

- *ustekinumab-aauz*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## USTEKINUMAB-AEKN IV

### Products Affected

- SELARSDI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## USTEKINUMAB-AEKN SQ

### Products Affected

- SELARSDI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## USTEKINUMAB-KFCE IV

### Products Affected

- YESINTEK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## USTEKINUMAB-KFCE SQ

### Products Affected

- YESINTEK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# VALBENZINE

**Products Affected**

- INGREZZA ORAL CAPSULE
- INGREZZA ORAL CAPSULE SPRINKLE
- INGREZZA ORAL CAPSULE THERAPY PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	TARDIVE DYSKINESIA (TD): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TD: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## VANDETANIB

### Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CURRENTLY STABLE ON CAPRELSA REQUIRES NO EXTRA CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

# VANZACAFITOR-TEZACAFITOR-DEUTIVACAFITOR

**Products Affected**

- ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: LIFETIME.
<b>Other Criteria</b>	CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## VEMURAFENIB

### Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MELANOMA: ZELBORAF WILL BE USED ALONE OR IN COMBINATION WITH COTELLIC
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

# VENETOCLAX

**Products Affected**

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	No

# VERICIGUAT

**Products Affected**

- VERQUVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL:12 MONTHS.
<b>Other Criteria</b>	HEART FAILURE (HF): INITIAL: 1) TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO ONE PREFERRED SGLT-2 INHIBITOR, AND 2) TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO ONE AGENT FROM ANY OF THE FOLLOWING STANDARD OF CARE CLASSES: (A) ACE INHIBITOR, ARB, OR ARNI, (B) BETA BLOCKER (BISOPROLOL, CARVEDILOL, METOPROLOL SUCCINATE), OR (C) ALDOSTERONE ANTAGONIST (SPIRONOLACTONE, EPLERENONE). INITIAL/RENEWAL: NO CONCURRENT USE WITH RIOCIGUAT OR PDE-5 INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## VIMSELTINIB

### Products Affected

- ROMVIMZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## VISMODEGIB

### Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## VONOPRAZAN

### Products Affected

- VOQUEZNA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: EROSIIVE ESOPHAGITIS (EE): DIAGNOSIS CONFIRMED BY ENDOSCOPY (E.G., LOS ANGELES CLASSIFICATION OF REFLUX ESOPHAGITIS GRADE A-D). NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (NERD): DIAGNOSIS CONFIRMED BY ENDOSCOPY AND DOES NOT HAVE PRESENCE OF VISIBLE EROSION (E.G., DOES NOT HAVE LOS ANGELES CLASSIFICATION OF REFLUX ESOPHAGITIS GRADE A-D).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: EE, NERD: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: H PYLORI: 30 DAYS. EE: 8 WEEKS. NERD: 4 WEEKS. RENEWAL: EE: 24 WEEKS.
<b>Other Criteria</b>	INITIAL: EE: TRIAL OF OR CONTRAINDICATION TO TWO PROTON PUMP INHIBITORS AT MAXIMUM DOSE FOR 8 WEEKS EACH. NERD: 1) NO PREVIOUS TREATMENT FAILURE WITH VOQUEZNA IN THE LAST 12 MONTHS, AND 2) TRIAL OF OR CONTRAINDICATION TO TWO PROTON PUMP INHIBITORS AT MAXIMUM DOSE FOR 8 WEEKS EACH. RENEWAL: EE: MAINTAINED A CLINICAL RESPONSE ON VOQUEZNA
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
Formulary ID: 26389 Version 9  
Last Updated 03/01/2026  
Effective: 03/01/2026

## VORASIDENIB

### Products Affected

- VORANIGO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## VORICONAZOLE SUSPENSION

### Products Affected

- *voriconazole oral suspension reconstituted*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CANDIDA INFECTIONS: 3 MOS. CONTINUATION OF THERAPY, ALL OTHER INDICATIONS: 6 MOS.
<b>Other Criteria</b>	CANDIDA INFECTIONS: CONTRAINDICATION TO OR UNABLE TO SWALLOW FLUCONAZOLE TABLETS. ALL INDICATIONS EXCEPT ESOPHAGEAL CANDIDIASIS: UNABLE TO SWALLOW TABLETS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No
<b>Prerequisite Therapy Required</b>	Yes

H1119\_PA26\_C  
 Formulary ID: 26389 Version 9  
 Last Updated 03/01/2026  
 Effective: 03/01/2026

## ZANIDATAMAB-HRII

### Products Affected

- ZIIHERA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ZANUBRUTINIB

### Products Affected

- BRUKINSA ORAL CAPSULE
- BRUKINSA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MANTLE CELL LYMPHOMA: INTOLERANCE TO CALQUENCE. CHRONIC LYMPHOCYTIC LEUKEMIA, SMALL LYMPHOCYTIC LYMPHOMA: INTOLERANCE TO CALQUENCE OR IMBRUVICA. WALDENSTROMS MACROGLOBULINEMIA: NO STEP REQUIRED.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

## ZENOCUTUZUMAB-ZBCO

### Products Affected

- BIZENGRI (750 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ZOLBETUXIMAB-CLZB

### Products Affected

- VYLOY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1119\_PA26\_C

Formulary ID: 26389 Version 9

Last Updated 03/01/2026

Effective: 03/01/2026

## ZONGERTINIB

### Products Affected

- HERNEXEOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

## ZURANOLONE

### Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 DAYS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

**INDEX**

**A**

abiraterone acetate ..... 7  
 ABIRATERONE ACETATE  
     MICRONIZED ..... 8  
 abirtega..... 7  
 ABOUTTIME PEN NEEDLE 30G X 8 MM  
     ..... 166, 184, 185  
 ABOUTTIME PEN NEEDLE 31G X 5 MM  
     ..... 166, 184, 185  
 ABOUTTIME PEN NEEDLE 31G X 8 MM  
     ..... 166, 184, 185  
 ABOUTTIME PEN NEEDLE 32G X 4 MM  
     ..... 166, 184, 185  
 ACTIMMUNE..... 189  
 ADEMPAS ..... 299, 300  
 ADVOCATE INSULIN PEN NEEDLE 32G  
     X 4 MM..... 166, 184, 185  
 ADVOCATE INSULIN PEN NEEDLES  
     29G X 12.7MM..... 166, 184, 185  
 ADVOCATE INSULIN PEN NEEDLES  
     31G X 5 MM..... 166, 184, 185  
 ADVOCATE INSULIN PEN NEEDLES  
     31G X 8 MM..... 166, 184, 185  
 ADVOCATE INSULIN PEN NEEDLES  
     33G X 4 MM..... 166, 184, 185  
 ADVOCATE INSULIN SYRINGE 29G X  
     1/2 ..... 166, 184, 185  
 ADVOCATE INSULIN SYRINGE 30G X  
     5/16 ..... 166, 184, 185  
 ADVOCATE INSULIN SYRINGE 31G X  
     5/16 ..... 166, 184, 185  
 AIMOVIG..... 122  
 AKEEGA ..... 244  
 ALCOHOL PREP PAD..... 166, 184, 185  
 ALCOHOL PREP PAD 70 %. 166, 184, 185  
 ALCOHOL PREP PADS PAD 70 % .... 166,  
     184, 185  
 ALCOHOL SWABS PAD..... 166, 184, 185  
 ALCOHOL SWABS PAD 70 % ... 166, 184,  
     185  
 ALECENSA..... 19  
 ALTRENO..... 366  
 ALUNBRIG ORAL TABLET 180 MG, 30  
     MG, 90 MG..... 57

ALUNBRIG ORAL TABLET THERAPY  
     PACK..... 57  
 ALVAIZ..... 109  
 ALYFTREK ORAL TABLET 10-50-125  
     MG, 4-20-50 MG ..... 395  
 alyq..... 337  
 ANKTIVA ..... 250  
 AQ INSULIN SYRINGE 31G X 5/16... 166,  
     184, 185  
 AQINJECT PEN NEEDLE 31G X 5 MM  
     ..... 166, 184, 185  
 AQINJECT PEN NEEDLE 32G X 4 MM  
     ..... 166, 184, 185  
 ARCALYST ..... 294, 295  
 ARIKAYCE..... 21  
 armodafinil..... 236  
 ASSURE ID DUO PRO PEN NEEDLES  
     31G X 5 MM..... 166, 184, 185  
 ASSURE ID INSULIN SAFETY SYR 29G  
     X 1/2..... 166, 184, 185  
 ASSURE ID INSULIN SAFETY SYR 31G  
     X 15/64..... 166, 184, 185  
 ASSURE ID PRO PEN NEEDLES 30G X 5  
     MM ..... 166, 184, 185  
 ATTRUBY ..... 10  
 AUGTYRO ORAL CAPSULE 160 MG, 40  
     MG ..... 287  
 AUM ALCOHOL PREP PADS PAD 70 %  
     ..... 166, 184, 185  
 AUM INSULIN SAFETY PEN NEEDLE  
     31G X 4 MM..... 166, 184, 185  
 AUM INSULIN SAFETY PEN NEEDLE  
     31G X 5 MM..... 166, 184, 185  
 AUM MINI INSULIN PEN NEEDLE 32G  
     X 4 MM..... 166, 184, 185  
 AUM MINI INSULIN PEN NEEDLE 32G  
     X 5 MM..... 166, 184, 185  
 AUM MINI INSULIN PEN NEEDLE 32G  
     X 6 MM..... 166, 184, 185  
 AUM MINI INSULIN PEN NEEDLE 32G  
     X 8 MM..... 166, 184, 185  
 AUM MINI INSULIN PEN NEEDLE 33G  
     X 4 MM..... 166, 184, 185

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

AUM MINI INSULIN PEN NEEDLE 33G X 5 MM.....	166, 184, 185	BD INSULIN SYRINGE 27G X 1/2.....	167, 184, 185
AUM MINI INSULIN PEN NEEDLE 33G X 6 MM.....	166, 184, 185	BD INSULIN SYRINGE 29G X 1/2.....	167, 184, 185
AUM PEN NEEDLE 32G X 4 MM.....	166, 184, 185	BD INSULIN SYRINGE HALF-UNIT 31G X 5/16.....	167, 184, 185
AUM PEN NEEDLE 32G X 5 MM.....	166, 184, 185	BD INSULIN SYRINGE MICROFINE 27G X 5/8.....	167, 184, 185
AUM PEN NEEDLE 32G X 6 MM.....	166, 184, 185	BD INSULIN SYRINGE MICROFINE 28G X 1/2.....	167, 184, 185
AUM PEN NEEDLE 33G X 4 MM.....	167, 184, 185	BD INSULIN SYRINGE U-100 1 ML .	167, 184, 185
AUM PEN NEEDLE 33G X 5 MM.....	167, 184, 185	BD INSULIN SYRINGE ULTRAFINE 29G X 1/2.....	167, 184, 185
AUM PEN NEEDLE 33G X 6 MM.....	167, 184, 185	BD INSULIN SYRINGE ULTRAFINE 30G X 1/2.....	167, 184, 185
AUM READYGARD DUO PEN NEEDLE 32G X 4 MM.....	167, 184, 185	BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM.....	167, 184, 185
AUM SAFETY PEN NEEDLE 31G X 4 MM.....	167, 184, 185	BD PEN NEEDLE MINI U/F 31G X 5 MM.....	167, 184, 185
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG.....	88	BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM.....	167, 184, 185
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG.....	88	BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM.....	167, 184, 185
AUSTEDO XR PATIENT TITRATION .	88	BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM.....	167, 184, 185
AVMAPKI FAKZYNJA CO-PACK.....	38	BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM.....	167, 184, 185
AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT.....	186	BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM.....	167, 184, 185
AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT.....	186	BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2.....	167, 184, 185
AYVAKIT .....	37	BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16.....	167, 184, 185
<b>B</b>		BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64.....	167, 184, 185
BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG.....	121	BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16.....	167, 184, 185
BD AUTOSHIELD DUO 30G X 5 MM	167, 184, 185	BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8.....	167, 184, 185
BD ECLIPSE SYRINGE 30G X 1/2.....	167, 184, 185	BD SWAB SINGLE USE REGULAR PAD .....	167, 184, 185
BD INSULIN SYR ULTRAFINE II 31G X 5/16 .....	167, 184, 185	BD SWABS SINGLE USE BUTTERFLY PAD.....	167, 184, 185
BD INSULIN SYRINGE 27.5G X 5/8..	167, 184, 185	BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64.....	167, 184, 185

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

BD VEO INSULIN SYR ULTRAFINE 31G X 15/64.....	167, 184, 185	CAREFINE PEN NEEDLES 32G X 5 MM .....	168, 184, 185
BD VEO INSULIN SYRINGE U/F 31G X 15/64 .....	167, 168, 184, 185	CAREFINE PEN NEEDLES 32G X 6 MM .....	168, 184, 185
BENDAMUSTINE HCL INTRAVENOUS SOLUTION.....	47	CAREONE INSULIN SYRINGE 30G X 1/2 .....	168, 184, 185
bendamustine hcl intravenous solution reconstituted.....	47	CAREONE INSULIN SYRINGE 31G X 5/16 .....	168, 184, 185
BENDEKA .....	47	CARETOUCH ALCOHOL PREP PAD 70 % .....	168, 184, 185
BENLYSTA SUBCUTANEOUS.....	44	CARETOUCH INSULIN SYRINGE 28G X 5/16 .....	168, 184, 185
BESREMI .....	307	CARETOUCH INSULIN SYRINGE 29G X 5/16 .....	168, 184, 185
betaine .....	50	CARETOUCH INSULIN SYRINGE 30G X 5/16 .....	168, 184, 185
BETASERON SUBCUTANEOUS KIT	187	CARETOUCH INSULIN SYRINGE 31G X 5/16 .....	168, 184, 185
bexarotene .....	52	CARETOUCH PEN NEEDLES 29G X 12MM .....	168, 184, 185
BIZENGRI (750 MG DOSE) .....	406	CARETOUCH PEN NEEDLES 31G X 5 MM .....	168, 184, 185
BORTEZOMIB INJECTION SOLUTION RECONSTITUTED 1 MG, 2.5 MG.....	54	CARETOUCH PEN NEEDLES 31G X 6 MM .....	168, 184, 185
bortezomib injection solution reconstituted 3.5 mg .....	54	CARETOUCH PEN NEEDLES 31G X 8 MM .....	168, 184, 185
BORUZU .....	54	CARETOUCH PEN NEEDLES 32G X 4 MM .....	168, 184, 185
bosentan oral tablet .....	55	CARETOUCH PEN NEEDLES 32G X 5 MM .....	168, 184, 185
BOSULIF ORAL CAPSULE 100 MG, 50 MG .....	56	CARETOUCH PEN NEEDLES 33G X 4 MM .....	168, 184, 185
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG.....	56	carglumic acid oral tablet soluble .....	64
BRAFTOVI ORAL CAPSULE 75 MG .	113	CAYSTON.....	42
BRUKINSA ORAL CAPSULE .....	405	CIMZIA (1 SYRINGE) PREFILLED SYRINGE KIT 200 MG/ML SUBCUTANEOUS.....	66, 67
BRUKINSA ORAL TABLET.....	405	CIMZIA (2 SYRINGE) .....	66, 67
<b>C</b>		CIMZIA SUBCUTANEOUS KIT 2 X 200 MG .....	66, 67
CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG.....	60	CIMZIA-STARTER .....	66, 67
CALQUENCE .....	9	CLEVER CHOICE COMFORT EZ 29G X 12MM .....	168, 184, 185
CAMCEVI .....	206	CLEVER CHOICE COMFORT EZ 33G X 4 MM .....	168, 184, 185
CAMZYOS .....	222		
CAPRELSA ORAL TABLET 100 MG, 300 MG .....	394		
CAREFINE PEN NEEDLES 29G X 12MM .....	168, 184, 185		
CAREFINE PEN NEEDLES 30G X 8 MM .....	168, 184, 185		
CAREFINE PEN NEEDLES 31G X 6 MM .....	168, 184, 185		
CAREFINE PEN NEEDLES 31G X 8 MM .....	168, 184, 185		
CAREFINE PEN NEEDLES 32G X 4 MM .....	168, 184, 185		

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

CLICKFINE PEN NEEDLES 31G X 8 MM ..... 168, 184, 185	COMFORT EZ PEN NEEDLES 33G X 6 MM ..... 169, 184, 185
CLICKFINE PEN NEEDLES 32G X 4 MM ..... 168, 184, 185	COMFORT EZ PEN NEEDLES 33G X 8 MM ..... 169, 184, 185
COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG ..... 59	COMFORT EZ PRO PEN NEEDLES 30G X 8 MM..... 169, 184, 185
COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG ..... 59	COMFORT EZ PRO PEN NEEDLES 31G X 4 MM..... 169, 184, 185
COMETRIQ (60 MG DAILY DOSE)..... 59	COMFORT EZ PRO PEN NEEDLES 31G X 5 MM..... 169, 184, 185
COMFORT ASSIST INSULIN SYRINGE 29G X 1/2..... 168, 184, 185	COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM..... 169, 184, 185
COMFORT ASSIST INSULIN SYRINGE 31G X 5/16..... 168, 184, 185	COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM..... 169, 184, 185
COMFORT EZ INSULIN SYRINGE 27G X 1/2..... 168, 184, 185	COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM..... 169, 184, 185
COMFORT EZ INSULIN SYRINGE 28G X 1/2..... 168, 184, 185	COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM..... 169, 184, 185
COMFORT EZ INSULIN SYRINGE 29G X 1/2..... 168, 184, 185	COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM..... 169, 184, 185
COMFORT EZ INSULIN SYRINGE 30G X 1/2..... 168, 184, 185	COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM..... 169, 184, 185
COMFORT EZ INSULIN SYRINGE 30G X 5/16..... 169, 184, 185	COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM..... 169, 184, 185
COMFORT EZ INSULIN SYRINGE 31G X 15/64..... 169, 184, 185	COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM..... 169, 184, 185
COMFORT EZ INSULIN SYRINGE 31G X 5/16..... 169, 184, 185	COPIKTRA..... 101
COMFORT EZ PEN NEEDLES 31G X 5 MM ..... 169, 184, 185	CORTROPHIN..... 72, 73
COMFORT EZ PEN NEEDLES 31G X 6 MM ..... 169, 184, 185	COSENTYX (300 MG DOSE)..... 311, 312
COMFORT EZ PEN NEEDLES 31G X 8 MM ..... 169, 184, 185	COSENTYX SENSOREADY (300 MG) ..... 311, 312
COMFORT EZ PEN NEEDLES 32G X 4 MM ..... 169, 184, 185	COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML ..... 311, 312
COMFORT EZ PEN NEEDLES 32G X 5 MM ..... 169, 184, 185	COSENTYX UNOREADY ..... 311, 312
COMFORT EZ PEN NEEDLES 32G X 6 MM ..... 169, 184, 185	COTELLIC ..... 71
COMFORT EZ PEN NEEDLES 32G X 8 MM ..... 169, 184, 185	CRESEMBA ORAL ..... 191
COMFORT EZ PEN NEEDLES 33G X 4 MM ..... 169, 184, 185	CURITY ALCOHOL PREPS PAD 70 % ..... 169, 184, 185
COMFORT EZ PEN NEEDLES 33G X 5 MM ..... 169, 184, 185	CURITY ALL PURPOSE SPONGES PAD 2..... 169, 184, 185
	CURITY GAUZE PAD 2..... 169, 184, 185
	CURITY GAUZE SPONGE PAD 2..... 169, 184, 185
	CURITY SPONGES PAD 2... 169, 184, 185
	CVS GAUZE PAD 2 ..... 169, 184, 185

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

CVS GAUZE STERILE PAD 2 .... 169, 184, 185  
 CVS ISOPROPYL ALCOHOL WIPES 169, 184, 185  
 CYLTEZO (2 PEN) ..... 16, 17  
 CYLTEZO (2 SYRINGE) ..... 16, 17  
 CYLTEZO-CD/UC/HS STARTER.... 16, 17  
 CYLTEZO-PSORIASIS/UV STARTER 16, 17

### D

dalfampridine er ..... 79  
 DANYELZA ..... 237  
 DANZITEN ..... 240  
 dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg ..... 81  
 DATROWAY ..... 82  
 DAURISMO ORAL TABLET 100 MG, 25 MG ..... 146  
 deferasirox granules ..... 84, 85  
 deferasirox oral tablet ..... 84, 85  
 DERMACEA GAUZE SPONGE PAD 2 ..... 169, 184, 185  
 DERMACEA IV DRAIN SPONGES PAD 2 ..... 169, 184, 185  
 DERMACEA NON-WOVEN SPONGES PAD 2 ..... 169, 184, 185  
 DERMACEA TYPE VII GAUZE PAD 2 ..... 169, 184, 185  
 DIACOMIT ORAL CAPSULE 250 MG, 500 MG ..... 335  
 DIACOMIT ORAL PACKET 250 MG, 500 MG ..... 335  
 DIATHRIVE PEN NEEDLE 31G X 5 MM ..... 169, 184, 185  
 DIATHRIVE PEN NEEDLE 31G X 6 MM ..... 169, 184, 185  
 DIATHRIVE PEN NEEDLE 31G X 8 MM ..... 169, 184, 185  
 DIATHRIVE PEN NEEDLE 32G X 4 MM ..... 169, 184, 185  
 diclofenac epolamine external ..... 91  
 diclofenac sodium external solution 2 % .. 90  
 dimethyl fumarate oral capsule delayed release 120 mg, 240 mg ..... 92  
 dimethyl fumarate starter pack oral capsule delayed release therapy pack ..... 92

dronabinol ..... 96  
 DROPLET INSULIN SYRINGE 29G X 1/2 ..... 169, 170, 184, 185  
 DROPLET INSULIN SYRINGE 30G X 1/2 ..... 170, 184, 185  
 DROPLET INSULIN SYRINGE 30G X 15/64 ..... 170, 184, 185  
 DROPLET INSULIN SYRINGE 30G X 5/16 ..... 170, 184, 185  
 DROPLET INSULIN SYRINGE 31G X 15/64 ..... 170, 184, 185  
 DROPLET INSULIN SYRINGE 31G X 5/16 ..... 170, 184, 185  
 DROPLET MICRON 34G X 3.5 MM... 170, 184, 185  
 DROPLET PEN NEEDLES 29G X 10MM ..... 170, 184, 185  
 DROPLET PEN NEEDLES 29G X 12MM ..... 170, 184, 185  
 DROPLET PEN NEEDLES 30G X 8 MM ..... 170, 184, 185  
 DROPLET PEN NEEDLES 31G X 5 MM ..... 170, 184, 185  
 DROPLET PEN NEEDLES 31G X 6 MM ..... 170, 184, 185  
 DROPLET PEN NEEDLES 31G X 8 MM ..... 170, 184, 185  
 DROPLET PEN NEEDLES 32G X 4 MM ..... 170, 184, 185  
 DROPLET PEN NEEDLES 32G X 5 MM ..... 170, 184, 185  
 DROPLET PEN NEEDLES 32G X 6 MM ..... 170, 184, 185  
 DROPLET PEN NEEDLES 32G X 8 MM ..... 170, 184, 185  
 DROPSAFE ALCOHOL PREP PAD 70 % ..... 170, 184, 185  
 DROPSAFE AUTOPROTECT DUO 31G X 4 MM ..... 170, 184, 185  
 DROPSAFE AUTOPROTECT DUO 31G X 5 MM ..... 170, 184, 185  
 DROPSAFE AUTOPROTECT DUO 31G X 8 MM ..... 170, 184, 185  
 DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM..... 170, 184, 185

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM..... 170, 184, 185  
 DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2..... 170, 184, 185  
 DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64..... 170, 184, 185  
 DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16..... 170, 184, 185  
 droxidopa ..... 97  
 DRUG MART ULTRA COMFORT SYR 29G X 1/2..... 170, 184, 185  
 DRUG MART ULTRA COMFORT SYR 30G X 5/16..... 170, 184, 185  
 DRUG MART UNIFINE PENTIPS 31G X 5 MM ..... 170, 184, 185  
 DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR .. 98, 100  
 DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE . 98, 100

### E

EASY COMFORT ALCOHOL PADS PAD ..... 170, 184, 185  
 EASY COMFORT INSULIN SYRINGE 29G X 5/16..... 170, 171, 184, 185  
 EASY COMFORT INSULIN SYRINGE 30G X 1/2..... 171, 184, 185  
 EASY COMFORT INSULIN SYRINGE 30G X 5/16..... 171, 184, 185  
 EASY COMFORT INSULIN SYRINGE 31G X 1/2..... 171, 184, 185  
 EASY COMFORT INSULIN SYRINGE 31G X 5/16..... 171, 184, 185  
 EASY COMFORT INSULIN SYRINGE 32G X 5/16..... 171, 184, 185  
 EASY COMFORT PEN NEEDLES 29G X 4MM ..... 171, 184, 185  
 EASY COMFORT PEN NEEDLES 29G X 5MM ..... 171, 184, 185  
 EASY COMFORT PEN NEEDLES 31G X 5 MM ..... 171, 184, 185  
 EASY COMFORT PEN NEEDLES 31G X 6 MM ..... 171, 184, 185  
 EASY COMFORT PEN NEEDLES 31G X 8 MM ..... 171, 184, 185

EASY COMFORT PEN NEEDLES 32G X 4 MM ..... 171, 184, 185  
 EASY COMFORT PEN NEEDLES 33G X 4 MM ..... 171, 184, 185  
 EASY COMFORT PEN NEEDLES 33G X 5 MM ..... 171, 184, 185  
 EASY COMFORT PEN NEEDLES 33G X 6 MM ..... 171, 184, 185  
 EASY GLIDE PEN NEEDLES 33G X 4 MM ..... 171, 184, 185  
 EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 %..... 171, 184, 185  
 EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2..... 171, 184, 185  
 EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2..... 171, 184, 185  
 EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16..... 171, 184, 185  
 EASY TOUCH FLIPLOCK INSULIN SY 31G X 5/16..... 171, 184, 185  
 EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2..... 171, 184, 185  
 EASY TOUCH INSULIN BARRELS U-100 1 ML..... 171, 184, 185  
 EASY TOUCH INSULIN SAFETY SYR 29G X 1/2..... 171, 184, 185  
 EASY TOUCH INSULIN SAFETY SYR 30G X 1/2..... 171, 184, 185  
 EASY TOUCH INSULIN SAFETY SYR 30G X 5/16..... 171, 184, 185  
 EASY TOUCH INSULIN SYRINGE 27G X 1/2..... 171, 184, 185  
 EASY TOUCH INSULIN SYRINGE 27G X 5/8..... 171, 184, 185  
 EASY TOUCH INSULIN SYRINGE 28G X 1/2..... 171, 184, 185  
 EASY TOUCH INSULIN SYRINGE 29G X 1/2..... 171, 184, 185  
 EASY TOUCH INSULIN SYRINGE 30G X 1/2..... 171, 184, 185  
 EASY TOUCH INSULIN SYRINGE 30G X 5/16..... 171, 172, 184, 185  
 EASY TOUCH INSULIN SYRINGE 31G X 5/16..... 172, 184, 185  
 EASY TOUCH PEN NEEDLES 29G X 12MM ..... 172, 184, 185

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

EASY TOUCH PEN NEEDLES 30G X 5 MM .....	172, 184, 185	EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16 .....	172, 184, 185
EASY TOUCH PEN NEEDLES 30G X 6 MM .....	172, 184, 185	EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2.....	172, 184, 185
EASY TOUCH PEN NEEDLES 30G X 8 MM .....	172, 184, 185	EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64.....	172, 184, 185
EASY TOUCH PEN NEEDLES 31G X 5 MM .....	172, 184, 185	EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16.....	172, 184, 185
EASY TOUCH PEN NEEDLES 31G X 6 MM .....	172, 184, 185	EMBECTA INSULIN SYRINGE 28G X 1/2 .....	172, 184, 185
EASY TOUCH PEN NEEDLES 31G X 8 MM .....	172, 184, 185	EMBECTA INSULIN SYRINGE U-100 27G X 5/8.....	172, 184, 185
EASY TOUCH PEN NEEDLES 32G X 4 MM .....	172, 184, 185	EMBECTA INSULIN SYRINGE U-100 28G X 1/2.....	172, 184, 185
EASY TOUCH PEN NEEDLES 32G X 5 MM .....	172, 184, 185	EMBECTA INSULIN SYRINGE U-500 .....	172, 184, 185
EASY TOUCH PEN NEEDLES 32G X 6 MM .....	172, 184, 185	EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM.....	172, 184, 185
EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM.....	172, 184, 185	EMBECTA PEN NEEDLE NANO 32G X 4 MM .....	172, 184, 185
EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM.....	172, 184, 185	EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM.....	172, 184, 185
EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM.....	172, 184, 185	EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM.....	172, 184, 185
EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2.....	172, 184, 185	EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM.....	172, 184, 185
EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2.....	172, 184, 185	EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM.....	172, 184, 185
EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16.....	172, 184, 185	EMBRACE PEN NEEDLES 29G X 12MM .....	172, 184, 185
EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16.....	172, 184, 185	EMBRACE PEN NEEDLES 30G X 5 MM .....	172, 184, 185
ELAHERE .....	233	EMBRACE PEN NEEDLES 30G X 8 MM .....	172, 184, 185
ELIGARD.....	207	EMBRACE PEN NEEDLES 31G X 5 MM .....	172, 184, 185
ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML.....	108	EMBRACE PEN NEEDLES 31G X 6 MM .....	173, 184, 185
eltrombopag olamine oral packet 12.5 mg, 25 mg .....	110, 111	EMBRACE PEN NEEDLES 31G X 8 MM .....	173, 184, 185
eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg .....	110, 111	EMBRACE PEN NEEDLES 32G X 4 MM .....	173, 184, 185
EMBECTA AUTOSHIELD DUO 30G X 5 MM .....	172, 184, 185	EMGALITY .....	141
EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64 .....	172, 184, 185	EMGALITY (300 MG DOSE).....	141
		EMRELIS .....	347
		ENBREL MINI.....	125, 126

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML.....	125, 126	FYARRO .....	321
ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	125, 126	<b>G</b>	
ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR	125, 126	GAUZE PADS PAD 2.....	173, 184, 185
ENSACOVE ORAL CAPSULE 100 MG, 25 MG .....	114	GAUZE TYPE VII MEDI-PAK PAD 2	173, 184, 185
EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG.....	324	GAVRETO .....	281
EPCLUSA ORAL TABLET.....	324	gefitinib .....	143
EPIDIOLEX.....	61	GILOTRIF .....	18
EPKINLY .....	118	glatiramer acetate subcutaneous solution	
EQL ALCOHOL SWABS PAD 70 %... 173, 184, 185		prefilled syringe 20 mg/ml, 40 mg/ml	147
EQL GAUZE PAD 2 .....	173, 184, 185	glatopa subcutaneous solution prefilled	
EQL INSULIN SYRINGE 29G X 1/2... 173, 184, 185		syringe 20 mg/ml, 40 mg/ml.....	147
EQL INSULIN SYRINGE 30G X 5/16. 173, 184, 185		GLOBAL ALCOHOL PREP EASE.....	173, 184, 185
ERBITUX .....	68	GLOBAL EASE INJECT PEN NEEDLES	
ERIVEDGE.....	400	29G X 12MM.....	173, 184, 185
ERLEADA ORAL TABLET 240 MG, 60 MG .....	26	GLOBAL EASE INJECT PEN NEEDLES	
erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg .....	123	31G X 5 MM.....	173, 184, 185
everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg .....	127	GLOBAL EASE INJECT PEN NEEDLES	
everolimus oral tablet soluble .....	128	31G X 8 MM.....	173, 184, 185
EXEL COMFORT POINT INSULIN SYR 29G X 1/2.....	173, 184, 185	GLOBAL EASE INJECT PEN NEEDLES	
EXEL COMFORT POINT INSULIN SYR 30G X 5/16.....	173, 184, 185	32G X 4 MM.....	173, 184, 185
EXEL COMFORT POINT PEN NEEDLE 29G X 12MM.....	173, 184, 185	GLOBAL EASY GLIDE INSULIN SYR	
EXXUA.....	144	31G X 15/64.....	173, 184, 185
<b>F</b>		GLOBAL INJECT EASE INSULIN SYR	
FASENRA .....	48, 49	30G X 1/2.....	173, 184, 185
FASENRA PEN.....	48, 49	GLUCOPRO INSULIN SYRINGE 30G X 1/2 .....	173, 184, 185
fentanyl citrate buccal lozenge on a handle .....	132	GLUCOPRO INSULIN SYRINGE 30G X 5/16 .....	173, 184, 185
fingolimod hcl.....	137	GLUCOPRO INSULIN SYRINGE 31G X 5/16 .....	173, 184, 185
FINTEPLA.....	131	GNP ALCOHOL SWABS PAD....	173, 184, 185
FOTIVDA.....	358	GNP CLICKFINE PEN NEEDLES 31G X 6 MM .....	173, 184, 185
FRUZAQLA ORAL CAPSULE 1 MG, 5 MG .....	139	GNP CLICKFINE PEN NEEDLES 31G X 8 MM .....	173, 184, 185
		GNP INSULIN SYRINGE 28G X 1/2 ..	173, 184, 185
		GNP INSULIN SYRINGE 29G X 1/2 ..	173, 184, 185
		GNP INSULIN SYRINGE 30G X 5/16	173, 184, 185
		GNP INSULIN SYRINGES 29GX1/2..	173, 184, 185

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

GNP INSULIN SYRINGES 30G X 5/16  
 ..... 173, 184, 185  
 GNP INSULIN SYRINGES 30GX5/16 173,  
 184, 185  
 GNP INSULIN SYRINGES 31GX5/16 173,  
 184, 185  
 GNP PEN NEEDLES 31G X 5 MM ..... 173,  
 184, 185  
 GNP PEN NEEDLES 32G X 4 MM ..... 173,  
 184, 185  
 GNP PEN NEEDLES 32G X 6 MM ..... 173,  
 184, 185  
 GNP STERILE GAUZE PAD 2.... 173, 184,  
 185  
 GNP ULTRA COM INSULIN SYRINGE  
 29G X 1/2..... 173, 184, 185  
 GNP ULTRA COM INSULIN SYRINGE  
 30G X 5/16..... 173, 184, 185  
 GOMEKLI ORAL CAPSULE 1 MG, 2 MG  
 ..... 232  
 GOMEKLI ORAL TABLET SOLUBLE232  
 GOODSENSE ALCOHOL SWABS PAD  
 70 % ..... 173, 184, 185  
 GOODSENSE CLICKFINE PEN NEEDLE  
 31G X 5 MM..... 174, 184, 185  
 GOODSENSE PEN NEEDLE PENFINE  
 31G X 8 MM..... 174, 184, 185

**H**

HAEGARDA SUBCUTANEOUS  
 SOLUTION RECONSTITUTED 2000  
 UNIT, 3000 UNIT ..... 58  
 HARVONI ORAL PACKET 33.75-150  
 MG, 45-200 MG ..... 200  
 HARVONI ORAL TABLET ..... 200  
 HEALTHWISE INSULIN SYR/NEEDLE  
 30G X 5/16..... 174, 184, 185  
 HEALTHWISE INSULIN SYR/NEEDLE  
 31G X 5/16..... 174, 184, 185  
 HEALTHWISE MICRON PEN NEEDLES  
 32G X 4 MM..... 174, 184, 185  
 HEALTHWISE SHORT PEN NEEDLES  
 31G X 5 MM..... 174, 184, 185  
 HEALTHWISE SHORT PEN NEEDLES  
 31G X 8 MM..... 174, 184, 185  
 HEALTHY ACCENTS UNIFINE PENTIP  
 29G X 12MM..... 174, 184, 185

HEALTHY ACCENTS UNIFINE PENTIP  
 31G X 5 MM..... 174, 184, 185  
 HEALTHY ACCENTS UNIFINE PENTIP  
 31G X 6 MM..... 174, 184, 185  
 HEALTHY ACCENTS UNIFINE PENTIP  
 31G X 8 MM..... 174, 184, 185  
 HEALTHY ACCENTS UNIFINE PENTIP  
 32G X 4 MM..... 174, 184, 185  
 H-E-B INCONTROL ALCOHOL PAD 174,  
 184, 185  
 H-E-B INCONTROL PEN NEEDLES 29G  
 X 12MM..... 174, 184, 185  
 H-E-B INCONTROL PEN NEEDLES 31G  
 X 5 MM..... 174, 184, 185  
 H-E-B INCONTROL PEN NEEDLES 31G  
 X 6 MM..... 174, 184, 185  
 H-E-B INCONTROL PEN NEEDLES 31G  
 X 8 MM..... 174, 184, 185  
 H-E-B INCONTROL PEN NEEDLES 32G  
 X 4 MM..... 174, 184, 185  
 HERCEPTIN HYLECTA..... 373  
 HERNEXEOS..... 408  
 HM STERILE ALCOHOL PREP PAD 174,  
 184, 185  
 HM STERILE PADS PAD 2.. 174, 184, 185  
 HM ULTICARE INSULIN SYRINGE 30G  
 X 1/2..... 174, 184, 185  
 HM ULTICARE INSULIN SYRINGE 31G  
 X 5/16..... 174, 184, 185  
 HM ULTICARE SHORT PEN NEEDLES  
 31G X 8 MM..... 174, 184, 185  
 HUMIRA (2 PEN) SUBCUTANEOUS  
 AUTO-INJECTOR KIT..... 12, 13  
 HUMIRA (2 SYRINGE)  
 SUBCUTANEOUS PREFILLED  
 SYRINGE KIT 10 MG/0.1ML, 20  
 MG/0.2ML, 40 MG/0.4ML, 40  
 MG/0.8ML ..... 12, 13  
 HUMIRA-CD/UC/HS STARTER  
 SUBCUTANEOUS AUTO-INJECTOR  
 KIT ..... 12, 13  
 HUMIRA-PED<40KG CROHNS  
 STARTER..... 12, 13  
 HUMIRA-PED>/=40KG CROHNS START  
 ..... 12, 13

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

HUMIRA-PED $\geq$ 40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT .....	12, 13	INSULIN SYRINGE 30G X 5/16 .	174, 184, 185
HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT .....	12, 13	INSULIN SYRINGE 31G X 5/16 .	174, 184, 185
HUMIRA-PSORIASIS/UEVIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT .....	12, 13	INSULIN SYRINGE/NEEDLE 27G X 1/2 .....	174, 184, 185
HYRNUO .....	317	INSULIN SYRINGE/NEEDLE 28G X 1/2 .....	174, 184, 185
<b>I</b>		INSULIN SYRINGE-NEEDLE U-100 27G X 1/2.....	174, 184, 185
IBRANCE.....	261	INSULIN SYRINGE-NEEDLE U-100 28G X 1/2.....	174, 184, 185
IBTROZI.....	341	INSULIN SYRINGE-NEEDLE U-100 30G X 5/16.....	174, 184, 185
icatibant acetate.....	157	INSULIN SYRINGE-NEEDLE U-100 31G X 1/4.....	174, 184, 185
ICLUSIG.....	279	INSULIN SYRINGE-NEEDLE U-100 31G X 5/16.....	174, 184, 185
IDHIFA .....	112	INSUPEN PEN NEEDLES 31G X 5 MM .....	174, 184, 185
imatinib mesylate oral tablet 100 mg, 400 mg .....	159	INSUPEN PEN NEEDLES 31G X 8 MM .....	174, 184, 185
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG .....	156	INSUPEN PEN NEEDLES 32G X 4 MM .....	175, 184, 185
IMBRUVICA ORAL SUSPENSION.....	156	INSUPEN PEN NEEDLES 33G X 4 MM .....	175, 184, 185
IMBRUVICA ORAL TABLET .....	156	INSUPEN SENSITIVE 32G X 6 MM... 175, 184, 185	
IMDELLTRA .....	343	INSUPEN SENSITIVE 32G X 8 MM... 175, 184, 185	
IMJUDO .....	375	INSUPEN ULTRAFIN 29G X 12MM.. 175, 184, 185	
IMKELDI.....	160	INSUPEN ULTRAFIN 30G X 8 MM ... 175, 184, 185	
IMPAVIDO.....	231	INSUPEN ULTRAFIN 31G X 6 MM... 175, 184, 185	
INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM.....	174, 184, 185	INSUPEN ULTRAFIN 31G X 8 MM... 175, 184, 185	
INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM.....	174, 184, 185	INSUPEN32G EXTR3ME 32G X 6 MM .....	175, 184, 185
INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM.....	174, 184, 185	ITOVEBI ORAL TABLET 3 MG, 9 MG .....	163
INCRELEX.....	223	IWILFIN .....	102
infliximab.....	164, 165	<b>J</b>	
INGREZZA ORAL CAPSULE.....	393	J & J GAUZE PAD 2.....	175, 184, 185
INGREZZA ORAL CAPSULE SPRINKLE .....	393	JAKAFI.....	309
INGREZZA ORAL CAPSULE THERAPY PACK.....	393		
INLURIYO .....	162		
INLYTA ORAL TABLET 1 MG, 5 MG..	40		
INQOVI .....	83		
INREBIC.....	130		
INSULIN SYRINGE 29G X 1/2 ...	174, 184, 185		

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

javygtor oral tablet .....	310
JAYPIRCA ORAL TABLET 100 MG, 50 MG .....	277
JEMPERLI.....	95
JYNARQUE ORAL TABLET .....	365
<b>K</b>	
KALYDECO.....	192
KENDALL HYDROPHILIC FOAM DRESS PAD 2 .....	175, 184, 185
KENDALL HYDROPHILIC FOAM PLUS PAD 2.....	175, 184, 185
KERENDIA .....	136
KESIMPTA.....	251
KEYTRUDA INTRAVENOUS SOLUTION.....	268
KEYTRUDA QLEX.....	269
KIMMTRAK .....	345
KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	24, 25
KINRAY INSULIN SYRINGE 29G X 1/2 .....	175, 184, 185
KISQALI (200 MG DOSE).....	291
KISQALI (400 MG DOSE).....	291
KISQALI (600 MG DOSE).....	291
KISQALI FEMARA (200 MG DOSE) ..	292
KISQALI FEMARA (400 MG DOSE) ..	292
KISQALI FEMARA (600 MG DOSE) ..	292
KMART VALU INSULIN SYRINGE 29G U-100 1 ML .....	175, 184, 185
KMART VALU INSULIN SYRINGE 30G U-100 0.3 ML .....	175, 184, 185
KMART VALU INSULIN SYRINGE 30G U-100 1 ML .....	175, 184, 185
KOSELUGO ORAL CAPSULE 10 MG, 25 MG.....	316
KOSELUGO ORAL CAPSULE SPRINKLE 5 MG, 7.5 MG.....	316
KRAZATI.....	11
KROGER INSULIN SYRINGE 30G X 5/16 .....	175, 184, 185
KROGER PEN NEEDLES 29G X 12MM .....	175, 184, 185
KROGER PEN NEEDLES 31G X 6 MM .....	175, 184, 185
KYNMOBI .....	28
KYNMOBI TITRATION KIT .....	28

<b>L</b>	
LANREOTIDE ACETATE.....	196
lapatinib ditosylate .....	197
LAZCLUZE ORAL TABLET 240 MG, 80 MG .....	199
LEADER INSULIN SYRINGE 28G X 1/2 .....	175, 184, 185
LEADER UNIFINE PENTIPS 31G X 5 MM .....	175, 184, 185
LEADER UNIFINE PENTIPS 32G X 4 MM .....	175, 184, 185
LEADER UNIFINE PENTIPS PLUS 31G X 5 MM.....	175, 184, 185
LEADER UNIFINE PENTIPS PLUS 31G X 8 MM.....	175, 184, 185
ledipasvir-sofosbuvir.....	200
lenalidomide.....	201
LENVIMA (10 MG DAILY DOSE) .....	202
LENVIMA (12 MG DAILY DOSE) .....	202
LENVIMA (14 MG DAILY DOSE) .....	202
LENVIMA (18 MG DAILY DOSE) .....	202
LENVIMA (20 MG DAILY DOSE) .....	202
LENVIMA (24 MG DAILY DOSE) .....	202
LENVIMA (4 MG DAILY DOSE) .....	202
LENVIMA (8 MG DAILY DOSE) .....	202
LEUPROLIDE ACETATE (3 MONTH) 205	
leuprolide acetate injection .....	204
l-glutamine oral packet .....	211
lidocaine external ointment 5 % .....	212
lidocaine-prilocaine external cream.....	213
LITETOUCH INSULIN SYRINGE 28G X 1/2 .....	175, 184, 185
LITETOUCH INSULIN SYRINGE 29G X 1/2 .....	175, 184, 185
LITETOUCH INSULIN SYRINGE 30G X 5/16 .....	175, 184, 185
LITETOUCH INSULIN SYRINGE 31G X 5/16 .....	175, 184, 185
LITETOUCH PEN NEEDLES 29G X 12.7MM .....	175, 184, 185
LITETOUCH PEN NEEDLES 31G X 5 MM .....	175, 184, 185
LITETOUCH PEN NEEDLES 31G X 6 MM .....	175, 184, 185
LITETOUCH PEN NEEDLES 31G X 8 MM .....	175, 184, 185

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

LITETOUCH PEN NEEDLES 32G X 4 MM .....	175, 184, 185	MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM .....	176, 184, 185
LIVTENCITY .....	221	MAXICOMFORT SYR 27G X 1/2	176, 184, 185
LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG .....	377	MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG .....	320
LOQTORZI .....	367	MAYZENT STARTER PACK .....	320
LORBRENA ORAL TABLET 100 MG, 25 MG .....	216	MEDIC INSULIN SYRINGE 30G X 5/16 .....	176, 184, 185
LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG .....	334	MEDICINE SHOPPE PEN NEEDLES 29G X 12MM .....	176, 184, 185
LUNSUMIO .....	235	MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM .....	176, 184, 185
LUPRON DEPOT (1-MONTH) .....	208, 209	MEDPURA ALCOHOL PADS 70 % EXTERNAL .....	176, 184, 185
LUPRON DEPOT (3-MONTH) .....	208, 209	MEIJER ALCOHOL SWABS PAD 70 % .....	176, 184, 185
LUPRON DEPOT (4-MONTH) .....	208, 209	MEIJER PEN NEEDLES 29G X 12MM .....	176, 184, 185
LUPRON DEPOT (6-MONTH) .....	208, 209	MEIJER PEN NEEDLES 31G X 6 MM	176, 185
LUPRON DEPOT-PED (3-MONTH) ....	210	MEIJER PEN NEEDLES 31G X 8 MM	176, 185
LUPRON DEPOT-PED (6-MONTH) ....	210	MEKINIST ORAL SOLUTION RECONSTITUTED .....	370
LUTRATE DEPOT .....	205	MEKINIST ORAL TABLET 0.5 MG, 2 MG .....	371
LYNOZYFIC INTRAVENOUS SOLUTION 200 MG/10ML, 5 MG/2.5ML .....	214	MEKTOVI .....	53
LYNPARZA ORAL TABLET .....	252	metyrosine .....	228
LYTGOBI (12 MG DAILY DOSE) .....	140	MICRODOT PEN NEEDLE 31G X 6 MM .....	176, 184, 185
LYTGOBI (16 MG DAILY DOSE) .....	140	MICRODOT PEN NEEDLE 32G X 4 MM .....	176, 184, 185
LYTGOBI (20 MG DAILY DOSE) .....	140	MICRODOT PEN NEEDLE 33G X 4 MM .....	176, 184, 185
<b>M</b>		mifepristone oral tablet 300 mg .....	230
MAGELLAN INSULIN SAFETY SYR 29G X 1/2 .....	175, 184, 185	MIPLYFFA .....	31
MAGELLAN INSULIN SAFETY SYR 30G X 5/16 .....	175, 184, 185	MIRASORB SPONGES 2 .....	176, 184, 185
MARGENZA .....	220	MM PEN NEEDLES 31G X 6 MM .....	176, 185
MAVENCLAD (10 TABS) .....	69	MM PEN NEEDLES 32G X 4 MM .....	176, 185
MAVENCLAD (4 TABS) .....	69	modafinil oral tablet 100 mg, 200 mg .....	236
MAVENCLAD (5 TABS) .....	69	MODEYSO .....	94
MAVENCLAD (6 TABS) .....	69	MONOJECT INSULIN SYRINGE 25G X 5/8 .....	176, 184, 185
MAVENCLAD (7 TABS) .....	69		
MAVENCLAD (8 TABS) .....	69		
MAVENCLAD (9 TABS) .....	69		
MAVYRET ORAL TABLET .....	148, 149		
MAXICOMFORT II PEN NEEDLE 31G X 6 MM .....	176, 184, 185		
MAXI-COMFORT INSULIN SYRINGE 28G X 1/2 .....	175, 184, 185		
MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM .....	175, 184, 185		

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

MONOJECT INSULIN SYRINGE 27G X 1/2 .....	176, 184, 185	NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML .....	225, 226, 227
MONOJECT INSULIN SYRINGE 28G X 1/2 .....	176, 184, 185	NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED .....	225, 226, 227
MONOJECT INSULIN SYRINGE 29G X 1/2 .....	176, 184, 185	NUEDEXTA .....	89
MONOJECT INSULIN SYRINGE 30G X 5/16 .....	176, 184, 185	NUPLAZID ORAL CAPSULE .....	274
MONOJECT INSULIN SYRINGE 31G X 5/16 .....	176, 184, 185	NUPLAZID ORAL TABLET 10 MG ...	274
MONOJECT INSULIN SYRINGE U-100 1 ML .....	176, 184, 185	NURTEC .....	297, 298
MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2 .....	176, 184, 185	NYVEPRIA .....	264
MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2 .....	176, 184, 185	<b>O</b>	
MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16 .....	176, 184, 185	ODOMZO .....	330
MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR .....	152	OFEV .....	241, 242
MS INSULIN SYRINGE 30G X 5/16... 176, 184, 185		OGIVRI .....	372
MS INSULIN SYRINGE 31G X 5/16... 176, 184, 185		OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG .....	245
<b>N</b>		OJEMDA ORAL SUSPENSION RECONSTITUTED .....	368
NERLYNX .....	238	OJEMDA ORAL TABLET .....	368
NIKTIMVO .....	39	OJJAARA .....	234
NINLARO .....	194	ONAPGO .....	27
nitisinone .....	246	ONUREG .....	41
NIVESTYM .....	135	OPDIVO .....	247
NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN- INJECTOR .....	327, 328	OPDIVO QVANTIG .....	248
NOVOFINE AUTOCOVER 30G X 8 MM .....	176, 184, 185	OPDUALAG .....	249
NOVOFINE PEN NEEDLE 32G X 6 MM .....	176, 184, 185	OPSUMIT .....	219
NOVOFINE PLUS PEN NEEDLE 32G X 4 MM .....	176, 184, 185	ORENCIA CLICKJECT .....	4, 5
NOVOTWIST PEN NEEDLE 32G X 5 MM .....	176, 184, 185	ORENCIA INTRAVENOUS .....	2, 3
NUBEQA .....	80	ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	4, 5
NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR .....	225, 226, 227	ORFADIN ORAL SUSPENSION .....	246
		ORGOVYX .....	286
		ORLISSA ORAL TABLET 150 MG, 200 MG .....	104, 105
		ORKAMBI ORAL TABLET .....	218
		ORSERDU ORAL TABLET 345 MG, 86 MG .....	103
		OSENVELT .....	86
		OTEZLA .....	29, 30
		OTEZLA XR .....	29, 30
		OTEZLA/OTEZLA XR INITIATION PK .....	29, 30
		oxandrolone oral .....	259
		OZEMPIC (0.25 OR 0.5 MG/DOSE) .....	151

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN- INJECTOR 4 MG/3ML .....	151	pirfenidone oral capsule .....	275, 276
OZEMPIC (2 MG/DOSE) .....	151	pirfenidone oral tablet 267 mg, 534 mg, 801 mg .....	275, 276
<b>P</b>		PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO- INJECTOR.....	188
pazopanib hcl oral tablet 200 mg, 400 mg .....	263	PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	188
PC UNIFINE PENTIPS 31G X 5 MM..	176, 184, 185	PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR .....	188
PC UNIFINE PENTIPS 31G X 6 MM..	176, 184, 185	PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	188
PC UNIFINE PENTIPS 31G X 8 MM..	177, 184, 185	POMALYST .....	278
PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML .....	266	posaconazole oral tablet delayed release	280
PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	266	PRECISION SURE-DOSE SYRINGE 30G X 5/16.....	177, 184, 185
PEMAZYRE.....	270	PREFERRED PLUS INSULIN SYRINGE 28G X 1/2.....	177, 184, 185
PEN NEEDLE/5-BEVEL TIP 31G X 8 MM .....	177, 184, 185	PREFERRED PLUS INSULIN SYRINGE 29G X 1/2.....	177, 184, 185
PEN NEEDLE/5-BEVEL TIP 32G X 4 MM .....	177, 184, 185	PREFERRED PLUS INSULIN SYRINGE 30G X 5/16.....	177, 184, 185
PEN NEEDLES 30G X 5 MM (OTC)...	177, 184, 185	PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM.....	177, 184, 185
PEN NEEDLES 30G X 8 MM	177, 184, 185	PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM.....	177, 184, 185
PEN NEEDLES 32G X 5 MM	177, 184, 185	PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM.....	177, 184, 185
penicillamine oral tablet.....	271, 272	PREVENT SAFETY PEN NEEDLES 31G X 6 MM.....	177, 184, 185
PENTIPS 29G X 12MM (RX)	177, 184, 185	PREVENT SAFETY PEN NEEDLES 31G X 8 MM.....	177, 184, 185
PENTIPS 31G X 5 MM (RX).	177, 184, 185	PREVYMIS ORAL TABLET .....	203
PENTIPS 31G X 8 MM (RX).	177, 184, 185	PRO COMFORT ALCOHOL PAD 70 % .....	177, 184, 185
PENTIPS 32G X 4 MM (RX).	177, 184, 185	PRO COMFORT INSULIN SYRINGE 30G X 1/2.....	177, 184, 185
PENTIPS GENERIC PEN NEEDLES 29G X 12MM.....	177, 184, 185	PRO COMFORT INSULIN SYRINGE 30G X 5/16.....	177, 184, 185
PENTIPS GENERIC PEN NEEDLES 31G X 6 MM.....	177, 184, 185	PRO COMFORT INSULIN SYRINGE 31G X 5/16.....	177, 184, 185
PENTIPS GENERIC PEN NEEDLES 32G X 6 MM.....	177, 184, 185	PRO COMFORT PEN NEEDLES 32G X 4 MM .....	177, 184, 185
PHARMACIST CHOICE ALCOHOL PAD .....	177, 184, 185	PRO COMFORT PEN NEEDLES 32G X 5 MM .....	177, 184, 185
PIP PEN NEEDLES 31G X 5MM 31G X 5 MM .....	177, 184, 185		
PIP PEN NEEDLES 32G X 4MM 32G X 4 MM .....	177, 184, 185		
PIQRAY (200 MG DAILY DOSE).....	20		
PIQRAY (250 MG DAILY DOSE).....	20		
PIQRAY (300 MG DAILY DOSE).....	20		

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

PRO COMFORT PEN NEEDLES 32G X 6 MM .....	177, 184, 185	QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM.....	178, 184, 185
PRO COMFORT PEN NEEDLES 32G X 8 MM .....	177, 184, 185	QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM.....	178, 184, 185
PRODIGY INSULIN SYRINGE 28G X 1/2 .....	177, 184, 185	QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM.....	178, 184, 185
PRODIGY INSULIN SYRINGE 31G X 5/16 .....	177, 184, 185	QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM.....	178, 184, 185
PURE COMFORT ALCOHOL PREP PAD .....	177, 184, 185	QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM.....	178, 184, 185
PURE COMFORT PEN NEEDLE 32G X 4 MM .....	177, 184, 185	QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM.....	178, 184, 185
PURE COMFORT PEN NEEDLE 32G X 5 MM .....	177, 184, 185	QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM.....	178, 184, 185
PURE COMFORT PEN NEEDLE 32G X 6 MM .....	177, 184, 185	quinine sulfate oral.....	283
PURE COMFORT PEN NEEDLE 32G X 8 MM .....	177, 184, 185	QULIPTA .....	35
PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM.....	177, 184, 185	<b>R</b>	
PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM.....	177, 184, 185	RA ALCOHOL SWABS PAD 70 %.....	178, 184, 185
PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM.....	177, 184, 185	RA INSULIN SYRINGE 29G X 1/2.....	178, 184, 185
PX SHORTLENGTH PEN NEEDLES 31G X 8 MM.....	177, 184, 185	RA INSULIN SYRINGE 30G X 5/16... ..	178, 184, 185
pyrimethamine oral .....	282	ra isopropyl alcohol wipes .....	178, 184, 185
<b>Q</b>		RA PEN NEEDLES 31G X 5 MM .....	178, 184, 185
QC ALCOHOL.....	177, 184, 185	RA PEN NEEDLES 31G X 8 MM .....	178, 184, 185
QC ALCOHOL SWABS PAD 70 %.....	178, 184, 185	RA STERILE PAD 2 .....	178, 184, 185
QC BORDER ISLAND GAUZE PAD 2 .....	178, 184, 185	RALDESY .....	374
QINLOCK.....	301	RAYA SURE PEN NEEDLE 29G X 12MM .....	178, 184, 185
QUICK TOUCH INSULIN PEN NEEDLE 29G X 12.7MM.....	178, 184, 185	RAYA SURE PEN NEEDLE 31G X 4 MM .....	178, 184, 185
QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM.....	178, 184, 185	RAYA SURE PEN NEEDLE 31G X 5 MM .....	178, 184, 185
QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM.....	178, 184, 185	RAYA SURE PEN NEEDLE 31G X 6 MM .....	178, 184, 185
QUICK TOUCH INSULIN PEN NEEDLE 31G X 6 MM.....	178, 184, 185	REALITY INSULIN SYRINGE 28G X 1/2 .....	178, 184, 185
QUICK TOUCH INSULIN PEN NEEDLE 31G X 8 MM.....	178, 184, 185	REALITY INSULIN SYRINGE 29G X 1/2 .....	178, 184, 185
QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM.....	178, 184, 185	REALITY SWABS PAD.....	178, 184, 185
		RELION ALCOHOL SWABS PAD.....	178, 184, 185

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

RELI-ON INSULIN SYRINGE 29G 0.3  
 ML..... 178, 184, 185  
 RELI-ON INSULIN SYRINGE 29G X 1/2  
 ..... 178, 184, 185  
 RELION INSULIN SYRINGE 31G X 15/64  
 ..... 178, 184, 185  
 RELION MINI PEN NEEDLES 31G X 6  
 MM ..... 178, 184, 185  
 RELION PEN NEEDLES 29G X 12MM  
 ..... 178, 184, 185  
 RELION PEN NEEDLES 31G X 6 MM178,  
 184, 185  
 RELION PEN NEEDLES 31G X 8 MM178,  
 184, 185  
 RESTORE CONTACT LAYER PAD 2 178,  
 184, 185  
 RETACRIT INJECTION SOLUTION  
 10000 UNIT/ML, 10000  
 UNIT/ML(1ML), 2000 UNIT/ML, 20000  
 UNIT/ML, 3000 UNIT/ML, 4000  
 UNIT/ML, 40000 UNIT/ML ..... 119, 120  
 RETEVMO ORAL CAPSULE 40 MG, 80  
 MG ..... 315  
 RETEVMO ORAL TABLET 120 MG, 160  
 MG, 40 MG, 80 MG ..... 315  
 REVCIVI..... 106  
 REVUFORJ ORAL TABLET 110 MG, 160  
 MG, 25 MG..... 290  
 REZDIFFRA..... 288  
 REZLIDHIA ..... 253  
 REZUROCK..... 45  
 RINVOQ..... 381, 382  
 RINVOQ LQ..... 381, 382  
 RITUXAN HYCELA ..... 304  
 ROMVIMZA ..... 399  
 ROZLYTREK ORAL CAPSULE 100 MG,  
 200 MG..... 115  
 ROZLYTREK ORAL PACKET ..... 116  
 RUBRACA ..... 308  
 RYBELSUS ..... 151  
 RYBELSUS (FORMULATION R2)..... 151  
 RYBREVANT ..... 23  
 RYBREVANT FASPRO ..... 22  
 RYDAPT..... 229  
 RYTELO..... 161

**S**  
 SAFETY INSULIN SYRINGES 29G X 1/2  
 ..... 178, 184, 185  
 SAFETY INSULIN SYRINGES 30G X 1/2  
 ..... 178, 184, 185  
 SAFETY INSULIN SYRINGES 30G X  
 5/16 ..... 178, 184, 185  
 SAFETY PEN NEEDLES 30G X 5 MM  
 ..... 178, 184, 185  
 SAFETY PEN NEEDLES 30G X 8 MM  
 ..... 178, 184, 185  
 sapropterin dihydrochloride oral tablet... 310  
 SB ALCOHOL PREP PAD 70 %.. 178, 184,  
 185  
 SB INSULIN SYRINGE 29G X 1/2 ..... 179,  
 184, 185  
 SB INSULIN SYRINGE 30G X 5/16 ... 179,  
 184, 185  
 SB INSULIN SYRINGE 31G X 5/16 ... 179,  
 184, 185  
 SCEMBLIX ORAL TABLET 100 MG, 20  
 MG, 40 MG..... 32  
 SECURESAFE INSULIN SYRINGE 29G  
 X 1/2..... 179, 184, 185  
 SECURESAFE SAFETY PEN NEEDLES  
 30G X 8 MM..... 179, 184, 185  
 SELARSDI ..... 385, 386, 387, 388  
 SEROSTIM SUBCUTANEOUS  
 SOLUTION RECONSTITUTED 4 MG,  
 5 MG, 6 MG..... 329  
 SIGNIFOR ..... 262  
 sildenafil citrate oral tablet 20 mg .. 318, 319  
 SIRTURO ..... 43  
 SKYRIZI..... 302, 303  
 SKYRIZI PEN ..... 302, 303  
 SM ALCOHOL PREP PAD ... 179, 184, 185  
 SM ALCOHOL PREP PAD 6-70 %  
 EXTERNAL ..... 179, 184, 185  
 SM ALCOHOL PREP PAD 70 % . 179, 184,  
 185  
 SM GAUZE PAD 2 ..... 179, 184, 185  
 sodium oxybate ..... 322, 323  
 sofosbuvir-velpatasvir..... 324  
 SOMATULINE DEPOT  
 SUBCUTANEOUS SOLUTION 60  
 MG/0.2ML, 90 MG/0.3ML ..... 196

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

SOMAVERT.....	267	SYMPAZAN.....	70
sorafenib tosylate .....	331	SYNRIBO .....	254
SPRAVATO (56 MG DOSE).....	124	<b>T</b>	
SPRAVATO (84 MG DOSE).....	124	TABRECTA .....	63
STERILE GAUZE PAD 2.....	179, 184, 185	tadalafil oral tablet 2.5 mg, 5 mg .....	338
STERILE PAD 2.....	179, 184, 185	TAFINLAR ORAL CAPSULE .....	76
STIVARGA .....	285	TAFINLAR ORAL TABLET SOLUBLE	77
STRENSIQ .....	33, 34	TAGRISSE.....	258
SUBVENITE ORAL SUSPENSION .....	195	TALVEY.....	342
sunitinib malate.....	336	TALZENNA .....	340
SURE COMFORT ALCOHOL PREP PAD		TASIGNA ORAL CAPSULE 150 MG, 200	
70 % .....	179, 184, 185	MG, 50 MG.....	239
SURE COMFORT INSULIN SYRINGE		TAVNEOS.....	36
28G X 1/2.....	179, 184, 185	TAZVERIK.....	344
SURE COMFORT INSULIN SYRINGE		TECHLITE INSULIN SYRINGE 29G X	
29G X 1/2.....	179, 184, 185	1/2 .....	179, 184, 185
SURE COMFORT INSULIN SYRINGE		TECHLITE PEN NEEDLES 32G X 4 MM	
30G X 1/2.....	179, 184, 185	.....	179, 184, 185
SURE COMFORT INSULIN SYRINGE		TECVAYLI.....	346
30G X 5/16.....	179, 184, 185	TEPMETKO .....	349
SURE COMFORT INSULIN SYRINGE		TERIPARATIDE SUBCUTANEOUS	
31G X 1/4.....	179, 184, 185	SOLUTION PEN-INJECTOR 560	
SURE COMFORT INSULIN SYRINGE		MCG/2.24ML .....	350
31G X 5/16.....	179, 184, 185	testosterone cypionate intramuscular	
SURE COMFORT PEN NEEDLES 29G X		solution 100 mg/ml, 200 mg/ml, 200	
12.7MM .....	179, 184, 185	mg/ml (1 ml) .....	352
SURE COMFORT PEN NEEDLES 30G X		testosterone enanthate intramuscular	
8 MM .....	179, 184, 185	solution.....	353
SURE COMFORT PEN NEEDLES 31G X		testosterone gel 1.62 % transdermal .....	351
5 MM .....	179, 184, 185	testosterone transdermal gel 12.5 mg/act	
SURE COMFORT PEN NEEDLES 31G X		(1%), 20.25 mg/act (1.62%), 25	
6 MM .....	179, 184, 185	mg/2.5gm (1%), 50 mg/5gm (1%).....	351
SURE COMFORT PEN NEEDLES 31G X		tetrabenazine .....	354
8 MM .....	179, 184, 185	TEVIMBRA.....	356
SURE COMFORT PEN NEEDLES 32G X		THALOMID ORAL CAPSULE 100 MG,	
4 MM (OTC).....	179, 184, 185	150 MG, 200 MG, 50 MG .....	355
SURE COMFORT PEN NEEDLES 32G X		THERAGAUZE PAD 2.....	179, 184, 185
4 MM (RX).....	179, 184, 185	TIBSOVO .....	193
SURE COMFORT PEN NEEDLES 32G X		TIGLUTIK.....	296
6 MM .....	179, 184, 185	TIVDAK .....	357
SURE-JECT INSULIN SYRINGE 31G X		TODAYS HEALTH PEN NEEDLES 29G	
5/16 .....	179, 184, 185	X 12MM.....	180, 184, 185
SURE-PREP ALCOHOL PREP PAD 70 %		TODAYS HEALTH SHORT PEN	
.....	179, 184, 185	NEEDLE 31G X 8 MM .....	180, 184, 185
SURGICAL GAUZE SPONGE PAD 2	179,	tolvaptan oral tablet therapy pack.....	365
184, 185			

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM.....	180, 184, 185	TRUE COMFORT PEN NEEDLES 32G X 4 MM .....	180, 184, 185
TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM.....	180, 184, 185	TRUE COMFORT PRO ALCOHOL PREP PAD 70 % .....	180, 184, 185
TOPCARE ULTRA COMFORT INS SYR 29G X 1/2.....	180, 184, 185	TRUE COMFORT PRO INSULIN SYR 30G X 1/2.....	180, 184, 185
TOPCARE ULTRA COMFORT INS SYR 30G X 5/16.....	180, 184, 185	TRUE COMFORT PRO INSULIN SYR 30G X 5/16.....	180, 184, 185
TOPCARE ULTRA COMFORT INS SYR 31G X 5/16.....	180, 184, 185	TRUE COMFORT PRO INSULIN SYR 31G X 5/16.....	180, 184, 185
torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg .....	127	TRUE COMFORT PRO INSULIN SYR 32G X 5/16.....	180, 184, 185
tramadol hcl oral solution .....	369	TRUE COMFORT PRO PEN NEEDLES 31G X 5 MM.....	180, 184, 185
TRELSTAR MIXJECT .....	378	TRUE COMFORT PRO PEN NEEDLES 31G X 6 MM.....	180, 184, 185
TREMFYA INTRAVENOUS .....	154, 155	TRUE COMFORT PRO PEN NEEDLES 31G X 8 MM.....	180, 184, 185
TREMFYA ONE-PRESS SUBCUTANEOUS SOLUTION PEN- INJECTOR.....	154, 155	TRUE COMFORT PRO PEN NEEDLES 32G X 4 MM.....	180, 184, 185
TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML .....	154, 155	TRUE COMFORT PRO PEN NEEDLES 32G X 5 MM.....	180, 184, 185
TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	154, 155	TRUE COMFORT PRO PEN NEEDLES 32G X 6 MM.....	180, 184, 185
TREMFYA-CD/UC INDUCTION.	154, 155	TRUE COMFORT PRO PEN NEEDLES 33G X 4 MM.....	180, 184, 185
tretinoin external cream .....	366	TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM.....	180, 184, 185
tretinoin external gel 0.01 %, 0.025 %....	366	TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM.....	180, 184, 185
trientine hcl oral capsule 250 mg .....	376	TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM.....	180, 184, 185
TRIKAFTA ORAL TABLET THERAPY PACK.....	107	TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM.....	180, 184, 185
TRIKAFTA ORAL THERAPY PACK..	107	TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM.....	181, 184, 185
TRUE COMFORT ALCOHOL PREP PADS PAD 70 % .....	180, 184, 185	TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM.....	181, 184, 185
TRUE COMFORT INSULIN SYRINGE 30G X 1/2.....	180, 184, 185	TRUEPLUS INSULIN SYRINGE 28G X 1/2 .....	181, 184, 185
TRUE COMFORT INSULIN SYRINGE 30G X 5/16.....	180, 184, 185	TRUEPLUS INSULIN SYRINGE 29G X 1/2 .....	181, 184, 185
TRUE COMFORT INSULIN SYRINGE 31G X 5/16.....	180, 184, 185	TRUEPLUS INSULIN SYRINGE 30G X 5/16 .....	181, 184, 185
TRUE COMFORT INSULIN SYRINGE 32G X 5/16.....	180, 184, 185		
TRUE COMFORT PEN NEEDLES 31G X 5 MM .....	180, 184, 185		
TRUE COMFORT PEN NEEDLES 31G X 6 MM .....	180, 184, 185		

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

TRUEPLUS INSULIN SYRINGE 31G X 5/16 .....	181, 184, 185	ULTICARE MINI PEN NEEDLES 32G X 6 MM .....	182, 184, 185
TRUEPLUS PEN NEEDLES 29G X 12MM .....	181, 184, 185	ULTICARE PEN NEEDLES 29G X 12.7MM (OTC).....	182, 184, 185
TRUEPLUS PEN NEEDLES 31G X 5 MM .....	181, 184, 185	ULTICARE PEN NEEDLES 29G X 12.7MM (RX) .....	182, 184, 185
TRUEPLUS PEN NEEDLES 31G X 6 MM .....	181, 184, 185	ULTICARE PEN NEEDLES 31G X 5 MM .....	182, 184, 185
TRUEPLUS PEN NEEDLES 31G X 8 MM .....	181, 184, 185	ULTICARE SHORT PEN NEEDLES 30G X 8 MM.....	182, 184, 185
TRUEPLUS PEN NEEDLES 32G X 4 MM .....	181, 184, 185	ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC).....	182, 184, 185
TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR .....	150	ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX) .....	182, 184, 185
TRUQAP ORAL TABLET .....	62	ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM.....	182, 184, 185
TRUQAP TABLET THERAPY PACK 160 MG ORAL .....	62	ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM.....	182, 184, 185
TRUXIMA .....	305, 306	ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM.....	182, 184, 185
TUKYSA ORAL TABLET 150 MG, 50 MG .....	379	ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM.....	182, 184, 185
TURALIO .....	273	ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM.....	182, 184, 185
TYENNE.....	359, 360, 361, 362	ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM.....	182, 184, 185
TYMLOS .....	1	ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2.....	182, 184, 185
<b>U</b>		ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16.....	182, 184, 185
UBRELVY.....	380	ULTILET ALCOHOL SWABS PAD ...	182, 184, 185
UDENYCA ONBODY .....	265	ULTILET PEN NEEDLE 29G X 12.7MM .....	182, 184, 185
ULTICARE INSULIN SAFETY SYR 29G X 1/2.....	181, 184, 185	ULTILET PEN NEEDLE 31G X 5 MM	182, 184, 185
ULTICARE INSULIN SYRINGE 28G X 1/2 .....	181, 184, 185	ULTILET PEN NEEDLE 31G X 8 MM	182, 184, 185
ULTICARE INSULIN SYRINGE 29G X 1/2 .....	181, 184, 185	ULTILET PEN NEEDLE 32G X 4 MM	182, 184, 185
ULTICARE INSULIN SYRINGE 30G X 1/2 .....	181, 184, 185	ULTRA COMFORT INSULIN SYRINGE 30G X 5/16.....	182, 184, 185
ULTICARE INSULIN SYRINGE 30G X 5/16 .....	181, 184, 185	ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM.....	182, 184, 185
ULTICARE INSULIN SYRINGE 31G X 1/4 .....	181, 184, 185	ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM.....	182, 184, 185
ULTICARE INSULIN SYRINGE 31G X 5/16 .....	181, 184, 185		
ULTICARE MICRO PEN NEEDLES 32G X 4 MM.....	181, 184, 185		
ULTICARE MINI PEN NEEDLES 30G X 5 MM .....	181, 184, 185		
ULTICARE MINI PEN NEEDLES 31G X 6 MM .....	181, 184, 185		

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM.....	182, 184, 185	ULTRA-THIN II INSULIN SYRINGE 29G X 1/2.....	183, 184, 185
ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM.....	182, 184, 185	ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM.....	183, 184, 185
ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2.....	182, 184, 185	ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM.....	183, 184, 185
ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16.....	182, 184, 185	ULTRA-THIN II PEN NEEDLES 29G X 12.7MM .....	183, 184, 185
ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16.....	182, 184, 185	UNIFINE OTC PEN NEEDLES 31G X 5 MM .....	183, 184, 185
ULTRA FLO INSULIN SYRINGE 29G X 1/2 .....	182, 184, 185	UNIFINE OTC PEN NEEDLES 32G X 4 MM .....	183, 184, 185
ULTRA FLO INSULIN SYRINGE 30G X 1/2 .....	182, 184, 185	UNIFINE PEN NEEDLES 32G X 4 MM .....	183, 184, 185
ULTRA FLO INSULIN SYRINGE 30G X 5/16 .....	182, 184, 185	UNIFINE PENTIPS 29G X 12MM	183, 184, 185
ULTRA FLO INSULIN SYRINGE 31G X 5/16 .....	182, 184, 185	UNIFINE PENTIPS 31G X 6 MM	183, 184, 185
ULTRA THIN PEN NEEDLES 32G X 4 MM .....	182, 184, 185	UNIFINE PENTIPS 31G X 8 MM	183, 184, 185
ULTRACARE INSULIN SYRINGE 30G X 1/2 .....	183, 184, 185	UNIFINE PENTIPS 32G X 4 MM	183, 184, 185
ULTRACARE INSULIN SYRINGE 30G X 5/16 .....	183, 184, 185	UNIFINE PENTIPS PLUS 29G X 12MM .....	183, 184, 185
ULTRACARE INSULIN SYRINGE 31G X 5/16 .....	183, 184, 185	UNIFINE PENTIPS PLUS 31G X 6 MM .....	183, 184, 185
ULTRACARE PEN NEEDLES 31G X 5 MM .....	183, 184, 185	UNIFINE PENTIPS PLUS 32G X 4 MM .....	183, 184, 185
ULTRACARE PEN NEEDLES 31G X 6 MM .....	183, 184, 185	UNIFINE PROTECT PEN NEEDLE 30G X 5 MM .....	183, 184, 185
ULTRACARE PEN NEEDLES 31G X 8 MM .....	183, 184, 185	UNIFINE PROTECT PEN NEEDLE 30G X 8 MM .....	183, 184, 185
ULTRACARE PEN NEEDLES 32G X 4 MM .....	183, 184, 185	UNIFINE PROTECT PEN NEEDLE 32G X 4 MM .....	183, 184, 185
ULTRACARE PEN NEEDLES 32G X 5 MM .....	183, 184, 185	UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM.....	183, 184, 185
ULTRACARE PEN NEEDLES 32G X 6 MM .....	183, 184, 185	UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM.....	183, 184, 185
ULTRACARE PEN NEEDLES 33G X 4 MM .....	183, 184, 185	UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM.....	183, 184, 185
ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2.....	182, 184, 185	UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM.....	183, 184, 185
ULTRA-THIN II INS SYR SHORT 30G X 5/16 .....	182, 183, 184, 185	UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM.....	183, 184, 185
ULTRA-THIN II INS SYR SHORT 31G X 5/16 .....	183, 184, 185	UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM.....	183, 184, 185

## Valor Health Plan 2026 Formulary Prior Authorization Criteria

UNIFINE ULTRA PEN NEEDLE 31G X 5 MM .....	183, 184, 185	VERIFINE PLUS PEN NEEDLE 31G X 5 MM .....	184, 185
UNIFINE ULTRA PEN NEEDLE 31G X 6 MM .....	183, 184, 185	VERIFINE PLUS PEN NEEDLE 31G X 8 MM .....	184, 185
UNIFINE ULTRA PEN NEEDLE 31G X 8 MM .....	183, 184, 185	VERIFINE PLUS PEN NEEDLE 32G X 4 MM .....	184, 185
UNIFINE ULTRA PEN NEEDLE 32G X 4 MM .....	183, 184, 185	VERQUVO .....	398
UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG .....	313	VERZENIO.....	6
UPTRAVI TITRATION.....	313	VITRAKVI ORAL CAPSULE 100 MG, 25 MG .....	198
ustekinumab-aauz .....	383, 384	VITRAKVI ORAL SOLUTION .....	198
<b>V</b>		VIVIMUSTA .....	47
VALCHLOR.....	224	VIZIMPRO .....	78
VALUE HEALTH INSULIN SYRINGE 29G X 1/2.....	184, 185	VONJO .....	260
VANFLYTA.....	284	VOQUEZNA .....	401
VANISHPOINT INSULIN SYRINGE 29G X 5/16.....	184, 185	VORANIGO .....	402
VANISHPOINT INSULIN SYRINGE 30G X 3/16.....	184, 185	voriconazole oral suspension reconstituted .....	403
VANISHPOINT INSULIN SYRINGE 30G X 5/16.....	184, 185	VOSEVI.....	325, 326
VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG.....	397	VOWST .....	129
VENCLEXTA STARTING PACK .....	397	VP INSULIN SYRINGE 29G X 1/2 .....	184, 185
VEOZAH .....	133, 134	VUMERITY .....	93
VERIFINE INSULIN PEN NEEDLE 29G X 12MM.....	184, 185	VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML.....	138
VERIFINE INSULIN PEN NEEDLE 31G X 5 MM.....	184, 185	VYLOY.....	407
VERIFINE INSULIN PEN NEEDLE 32G X 6 MM.....	184, 185	VYNDAMAX.....	339
VERIFINE INSULIN SYRINGE 28G X 1/2 .....	184, 185	<b>W</b>	
VERIFINE INSULIN SYRINGE 29G X 1/2 .....	184, 185	WEBCOL ALCOHOL PREP LARGE PAD 70 % .....	184, 185
VERIFINE INSULIN SYRINGE 30G X 1/2 .....	184, 185	WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM.....	184, 185
VERIFINE INSULIN SYRINGE 30G X 5/16 .....	184, 185	WELIREG.....	46
VERIFINE INSULIN SYRINGE 31G X 5/16 .....	184, 185	WINREVAIR.....	332, 333
		<b>X</b>	
		XALKORI ORAL CAPSULE.....	74
		XALKORI ORAL CAPSULE SPRINKLE 150 MG, 20 MG, 50 MG .....	75
		XDEMVI .....	217
		XELJANZ.....	363, 364
		XELJANZ XR .....	363, 364
		XERMELO .....	348
		XGEVA.....	87
		XIFAXAN ORAL TABLET 200 MG, 550 MG .....	293
		XOLAIR .....	255, 256, 257

Valor Health Plan 2026 Formulary Prior Authorization Criteria

XOSPATA .....	145	YESINTEK.....	389, 390, 391, 392
XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG .....	314	YONSA.....	8
XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG, 40 MG .....	314	YUFLYMA (1 PEN).....	14, 15
XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG .....	314	YUFLYMA (2 SYRINGE).....	14, 15
XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG..	314	YUFLYMA-CD/UC/HS STARTER ..	14, 15
XPOVIO (60 MG TWICE WEEKLY)...	314	<b>Z</b>	
XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG, 80 MG .....	314	ZEJULA ORAL CAPSULE .....	243
XPOVIO (80 MG TWICE WEEKLY)...	314	ZEJULA ORAL TABLET.....	243
XTANDI ORAL CAPSULE.....	117	ZELBORAF.....	396
XTANDI ORAL TABLET 40 MG, 80 MG .....	117	ZEVRX STERILE ALCOHOL PREP PAD PAD 70 % .....	184, 185
<b>Y</b>		ZIIHERA.....	404
YERVOY.....	190	ZIRABEV .....	51
		ZOLADEX.....	153
		ZTALMY .....	142
		ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG.....	409
		ZYDELIG .....	158
		ZYKADIA ORAL TABLET .....	65
		ZYNLONTA.....	215
		ZYNYZ.....	289